

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Optimizing patient active role with a user-centered eHealth platform (CONCERTO+) in chronic diseases management: A study protocol for a pilot cluster randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028554
Article Type:	Protocol
Date Submitted by the Author:	14-Dec-2018
Complete List of Authors:	Gagnon, Marie-Pierre; University of Laval, Ndiaye, Mame-Awa; University of Laval, Faculty of nursing Larouche, Alain; Groupe Santé Concerto Chabot, Guylaine; Groupe Santé Concerto Chabot, Christian; International Business Machines Corporation Buyl, Ronald; Vrje Universiteit Brussel, Jette, Belgium Fortin, Jean-Paul; Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval; Université Laval, Département de médecine sociale et préventive Giguere, Anik; Laval university research centre on primary care and services, ; Université Laval Faculte de medecine, Family Medicine and Emergency medicine LeBlanc, Annie; Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval Legare, France; CHU de Quebec and Université Laval, Motulsky, Aude; Department of Health Management, Evaluation and Policy, School of Public Health Sicotte, Claude; Université de Montreal Faculte de medecine, Witteman, Holly; Faculté de médecine de l'Université Laval Kavanagh, Eric; École de design, Université Laval Lépinay, Frédéric; École de design, Université Laval Roberge, Jacynthe; École de design, Université Laval, Délétröz, Carole; School of Health Sciences (HESAV), HES-SO University of Applied Sciences and Arts Western Switzerland Lausanne Abbasgholizadeh Rahimi, Samira; CHU de Quebec-Université Laval
Keywords:	Chronic disease management, Multimorbidity, eHealth, Health Literacy, User-centered design, Patient and caregiver engagement

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Optimizing patient active role with a user-centered eHealth platform (CONCERTO+) in chronic diseases management: A study protocol for a pilot cluster randomized controlled trial

Marie-Pierre Gagnon^{1, 2}, Mame Awa Ndiaye², Alain Larouche³, Guylaine Chabot, Christian Chabot⁴, Ronald Buyl⁵, Jean-Paul Fortin⁶, Anik Giguère⁷, Annie LeBlanc⁶, France Légaré^{1, 6}, Aude Motulsky⁸, Claude Sicotte⁸, Holly O.Witteman⁷, Éric Kavanagh⁹, Frédéric Lépinay⁹, Jacynthe Roberge⁹, Carole Délétroz¹⁰, Samira Rahimi Abbasgholizadeh¹¹

Author's affiliations

¹ Research Centre of the CHU de Québec, Hôpital Saint-François d'Assise, 10 rue de l'Espinay, D6726, Quebec City, QC, G1L 3 L5, Canada

² Faculty of Nursing, Université Laval, Quebec City, QC, Canada

³ Groupe Santé Concerto, Montréal, Qc, Canada

⁴ International Business Machines Corporation, Quebec City, Qc, Canada

⁵ Vrje Universiteit Brussel, Jette, Belgium

1
2
3 ⁶ Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval,
4 Quebec city, Canada
5
6

7 ⁷ Department of Family and Emergency Medicine, Université Laval, Quebec City, QC, Canada
8
9

10 ⁸ Department of Health Management, Evaluation and Policy, School of Public Health, Université
11 de Montréal, Qc, Canada
12
13

14 ⁹ École de design, Université Laval, Quebec City, QC, Canada
15
16

17 ¹⁰ School of Health Sciences (HESAV), HES-SO University of Applied Sciences and Arts Western
18 Switzerland Lausanne.
19
20

21 ¹¹Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada
22
23

24 Correspondence to

25
26
27 Pr Marie-Pierre Gagnon; marie-pierre.gagnon@fsi.ulaval.ca
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction Multimorbidity increases care needs and primary care use among people with chronic disease. The Concerto Health Program (CHP) has been developed to optimize chronic disease management in primary care services. However, in its current version, the CHP primarily targets clinicians and does not aim to answer directly patients' and their informal caregivers' needs for chronic disease management. Various studies have shown that interventions that increase patient activation level are associated with better health outcomes. Furthermore, educational tools must be adapted to patients and caregivers in terms of health literacy and usability. This project aims to develop, implement and evaluate a user-centered, multifunctional and personalized eHealth platform (CONCERTO+) to promote a more active patient role in chronic disease management and decision-making.

1
2
3 **Methods and analysis** This project uses a collaborative research approach,
4
5
6
7 aiming at the personalization of CHP through 3 phases: 1) the development of
8
9
10
11 one module of an eHealth platform combining scientific evidence and user-
12
13
14 centered design; 2) a feasibility study of CONCERTO+ through a pilot cluster
15
16
17 randomized controlled trial where patients with chronic disease from a primary
18
19
20
21
22 healthcare practice will receive CONCERTO+ during 6 months and be compared
23
24
25
26 to patients from a control practice receiving usual care; and 3) an analysis of
27
28
29
30 CONCERTO+ potential for scaling up. To do so, we will conduct two focus
31
32
33
34 groups with patients and informal caregivers and individual interviews with health
35
36
37 professionals at the two study sites, as well as health care managers, information
38
39
40
41 officers and representatives of the Ministry of Health.
42
43
44
45
46
47
48
49

50 **Ethics and dissemination** This study has ethical approval from Ethics Committee
51
52
53 of Université Laval. The findings will be used to inform the effectiveness of
54
55
56
57
58
59
60

1
2
3 CONCERTO+ to improve management care in chronic disease. We will
4
5
6
7 disseminate findings through presentations in scientific conferences and
8
9
10
11 publication in peer reviewed journals.
12
13
14
15
16
17
18
19

20 **Trial registration:** Clinicaltrials.gov ID: NCT03628963
21
22
23

24 **Keywords:** Chronic disease management, Multimorbidity, eHealth, Patient and
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

caregiver engagement, Health Literacy, User-centered design.

Strengths and limitations of this study

- The design of a user-centered technological solution is adapted to

1
2
3
4 chronic disease patients' needs and their literacy level.
5
6
7

- 8
- 9 • The inclusion of the caregivers in the use of CONCERTO+ is a novelty.
10
11
 - 12 • The pilot test will provide data for feasibility, acceptability and usefulness
13
14 of CONCERTO+.
15
16
 - 17 • Good potential for sustainability given that it will be implemented in the
18
19 real context of primary care practice with the collaboration of clinical
20
21 teams.
22
23
 - 24 • As a limitation, this project seems ambitious for its entire achievement
25
26 in two years.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Background

Chronic diseases are the number one cause of mortality in the world, and account for nearly 70% of deaths [1]. In Canada and around the world, multimorbidity, which means people who have more than two chronic diseases, is increasing [2]. In addition to often making life more difficult for the people living with these conditions, such the rise in cases is putting pressure on the Canadian healthcare system and causing over-consumption of care and services [3]. In the Province of Quebec, 45% of people aged 20 and over have more than two chronic diseases [4], and 80% of chronic disease consultations are done in primary health care services [5]. Multimorbidity increases care needs as well as the complexity of

1
2
3 health care services required in primary care, especially when it comes to applying
4
5
6
7 recommendations for good clinical practices [5]. The total cost of the six most
8
9
10 common chronic diseases in Quebec (ischemic heart disease, cerebrovascular
11
12
13 disease, chronic obstructive pulmonary disease, cancer, hypertension and
14
15
16 diabetes) has been estimated at 8, 1 billion, and this may rise up to \$13 billion in
17
18
19
20
21
22 2030 if no substantial change is made [6].
23
24

25
26
27 In Quebec, primary care services have the main responsibility to support people
28
29
30 with chronic diseases and their informal caregivers, jointly with other stakeholders
31
32
33 of the local health network [7, 8]. However, primary care services suffer from many
34
35
36
37 challenges and organizational constraints, in particular, the difficulty of access –
38
39
40
41 with a large proportion of Quebecers without a family doctor – and the wait times
42
43
44
45 that are among the longest in Canada [9, 10]. Furthermore, the fragmentation of
46
47
48
49 health care processes and the gaps in information transfer are recognized sources
50
51
52
53 of inefficiency, that make critical the integration and continuity of care for chronic
54
55
56
57
58
59
60

1
2
3 diseases [7, 11]. To overcome these issues, many approaches linking healthcare
4
5
6
7 providers, patients, caregivers and the organization of health care services are
8
9
10 promoted [12]. The central role of patients in the management of their disease,
11
12
13
14 which depends on their active involvement, is recognized as a key component in
15
16
17
18 chronic disease management [13].
19
20
21
22

23 Active patient involvement requires that patients have the knowledge, skills and
24
25
26 self-confidence to manage their health and healthcare [14]. Various studies have
27
28
29
30 shown that interventions increasing patient activation level are associated with
31
32
33
34 better health outcomes [15-22] and decreased costs [23]. However, active patient
35
36
37
38 involvement and the quality of the interactions with health providers will partially
39
40
41
42 depend on patient's knowledge of the disease and the needed care, in addition to
43
44
45
46 their interpersonal skills as well as their ability to communicate their expectations,
47
48
49
50 needs and preferences to their healthcare team [24, 25]. It is therefore important
51
52
53
54 to offer patients and caregivers relevant information adapted to their health literacy
55
56
57
58
59
60

1
2
3 level. According the following definition, “Health literacy is linked to literacy and
4
5
6
7 entails people’s knowledge, motivation and competences to access, understand,
8
9
10
11 appraise and apply health information in order to make judgements and take
12
13
14 decisions in everyday life concerning health care, disease prevention and health
15
16
17 promotion to maintain or improve quality of life during the life course” [26]. For their
18
19
20
21 part, health professionals must also have the communicational and interpersonal
22
23
24 skills required to work in a team and share information appropriately with patients
25
26
27 in order to support their active involvement [24]. Thus, it becomes important to act
28
29
30
31 in advance by supporting patients’ autonomy and involvement in the care dynamic,
32
33
34 and by promoting informational and educational relationships in disease
35
36
37 management [25-27]. Therefore, it is crucial that information and educational tools
38
39
40
41 are adapted to patients and caregivers in terms of literacy level and presentation
42
43
44
45
46
47
48 [28-30].
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 eHealth technologies offer a potential to support chronic disease management.
4
5

6
7 Some studies have shown positive effects on clinical processes (better adherence
8
9
10
11 to care protocol, reduced errors and improved monitoring and callback rates), on
12
13
14
15 quality of care and effectiveness, and on patient outcomes [31-36].
16
17

18
19 Systematic reviews support the role of electronic personal health records and
20
21
22
23 electronic portals allowing patient access to their health records in order to promote
24
25
26
27 their active participation in their care [37-39]. However, to achieve expected
28
29
30
31 outcomes, eHealth technologies first should be adopted and used in an appropriate
32
33
34
35 manner by patients and health professionals [40]. Therefore, end-user involvement
36
37
38
39 in the development of eHealth solutions is an imperative [41]. Moreover, eHealth
40
41
42
43 literacy, which is inspired by the health literacy concept but focuses specifically on
44
45
46
47 optimal eHealth solutions use, should be considered in order to ensure that the
48
49
50
51 solutions are adapted to the capabilities of targeted users [30, 42]. While the
52
53
54
55
56
57
58
59
60 number of eHealth solutions continues to increase, with more than 325,000 mobile

1
2
3 health applications in 2017 [43], the majority of them (53%) are used by less than
4
5
6
7 5,000 people and are often abandoned after a short trial period [44-46]. User
8
9
10 involvement – including patients, informal caregivers and health professionals – is
11
12
13 identified to be among the issues to ensure that eHealth solutions have a real
14
15
16 impact, all the stakeholders must be promoted throughout the different stages of
17
18
19 technology development, from conception to assessment [47]. Based on efficient
20
21
22 chronic care models, high-potential technologies and patient involvement as active
23
24
25 partner of their care, we suggest to develop an innovative and mobilizing project in
26
27
28 order to improve patient care and experience.
29
30
31
32
33
34
35
36
37

38 Methods and analysis:

39
40
41
42
43 The following methods adhere to the Standard Protocol Items Recommendations
44
45
46
47 for Interventional Trials (SPIRIT) guidelines for the reporting of study protocols.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 This project is a collaborative work involving IT developers from CHP, designers,
5
6
7 clinicians, technological partners and patient representatives. The aim is to
8
9
10 develop, implement and evaluate a module of a multifunctional and personalized
11
12
13 eHealth platform, CONCERTO+, through a pilot study for optimizing patient active
14
15
16 role in medical follow-up, decision-making, satisfaction towards healthcare
17
18
19 services and quality of life. The specific objectives are to: 1) develop a module of a
20
21
22 multifunctional and personalized eHealth platform integrated to the CHP for
23
24
25 patients and caregivers allowing them to engage in the follow-up and management
26
27
28 of their chronic diseases; 2) test the integration of CONCERTO+ in monitoring care
29
30
31 pathways of three frequent co-existing chronic diseases (diabetes, hypertension,
32
33
34 dyslipidemia) and assess the usefulness and acceptability of the solution for
35
36
37 patients with chronic diseases and their caregivers; 3) assess the scalability of the
38
39
40
41
42
43
44
45
46
47
48
49 CONCERTO+ solution.
50

51 52 53 Phase 1: Development of the eHealth solution module 54 55 56 57 58 59 60

1
2
3 We will conduct a rapid literature review on the effects of eHealth interventions for
4
5
6
7 supporting active involvement of patients with chronic diseases in their primary
8
9
10
11 care team. For this purpose, we will follow the rapid review method suggested by
12
13
14 Lawani et al. [48] and consider the latest evidence on eHealth interventions for
15
16
17
18 chronic diseases monitoring and care. We will consider the following “Problem,
19
20
21
22 Intervention, Comparison, Outcomes (PICO)” elements: (P): three targeted chronic
23
24
25
26 diseases (diabetes, high blood pressure, dyslipidemia), alone or combined; (I) all
27
28
29 eHealth interventions implemented in primary care and that directly involve patients
30
31
32
33 (e.g. Electronic Medical Records, patient diary, patient portal, specific
34
35
36
37 computerized monitoring for a chronic disease and technological interventions
38
39
40
41 focused on lifestyle modifications; (C): routine follow-up; (O): Health outcomes
42
43
44
45 specific to the disease (e.g. HbA1c for diabetes), generic health outcomes (e.g.
46
47
48
49 mortality, quality of life), patient outcomes (e.g. involvement, personal efficacy) and
50
51
52
53 practices and process outcomes (e.g. test numbers, emergency visits,
54
55
56
57
58
59
60

1
2
3 hospitalizations). First, we will start to consult existing systematic reviews, in
4
5
6
7 particular that of Irizarry et al. [38], and a review of reviews that we have already
8
9
10
11 completed [49]. We will also document issues relating to needs, expectations and
12
13
14 concerns in terms of eHealth solutions for patients, their informal caregivers, and
15
16
17 health care providers. This information will provide evidence summaries describing
18
19
20 each eHealth solution associated with each targeted health issues, as well as
21
22
23 information on the risks and benefits of these solutions. We will then use the
24
25
26 methods suggested by Giguère et al. [50] to develop Decision Boxes to involve
27
28
29 patients and their informal caregivers in the choice of functionalities and contents
30
31
32 to develop in the CONCERTO+ solution, in line with an integrated care system (**Fig.**
33
34
35
36
37
38
39
40
41 **1**).
42
43
44

45 A first prototype will be developed by the design and technology teams, in close
46
47
48 collaboration with researchers, health professionals and patient representatives
49
50
51 who will identify the functionalities to include in the CONCERTO+ solution. Given
52
53
54
55
56
57
58
59
60

1
2
3 the time limit of the project, we will classify the required functionalities in 3 types:
4
5
6

7 1) essential and priority; 2) important but not priority; 3) required in the future.
8
9

10 For the development of the eHealth platform module, a user-centered approach
11
12 will be used, based on three cycles with users. Iterative testing sessions will take
13
14 place at the usability laboratory of UL lead by HW, providing all the equipment
15
16 needed to conduct usability studies. Students in graphic and interaction design,
17
18 under the direction of three experts from the School of Design of UL (EK, FLP, JR),
19
20 will participate in the development of the platform's visual environment. An expert
21
22 in eHealth literacy (CD) will ensure that contents of the clinical monitoring tools
23
24 already integrated in the CHP are adapted to a general audience according to
25
26 recommendations of the Health Literacy Guide [51], in addition of tools that provide
27
28 understandable information (e.g link to a popular glossary of medical terms:
29
30 [https://publications.santemontreal.qc.ca/uploads/tx_asssmpublications/litteratie_v
33
34 9.pdf](https://publications.santemontreal.qc.ca/uploads/tx_asssmpublications/litteratie_v
31
32 9.pdf)).
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The integration of the CONCERTO+ solution with the CHP will be ensured by the
4
5
6
7 Concerto Health Group team who will work closely with the designers and
8
9
10
11 researchers. Health professionals in primary care services from the sites
12
13
14 participating in the pilot project will also be consulted to validate the match between
15
16
17 the CONCERTO + solution and care pathways for professionals offered by the
18
19
20
21
22 CHP.
23
24
25

26 Patient and Public Involvement

27
28
29
30
31 **How was the development of the research question and outcome measures**
32
33
34 **informed by patients' priorities, experience, and preferences?**
35
36
37
38

39 A patient partner (informal caregiver) is involved as research partner at key stages
40
41
42 of the study. His experience in caring of a patient with diabetes informed us on
43
44
45 needs of patients, research focus, methods for collecting data for the study and
46
47
48
49
50 dissemination strategy through patient and citizen groups associations.
51
52
53

54
55 **How did you involve patients in the design of this study?**
56
57
58
59
60

1
2
3 Our patient partner is invited at each research team meeting to make sure that the
4
5
6
7 research questions are aligned with patients' needs. He gives his input in refining
8
9
10
11 the focus of the research questions. He made valuable contributions in the design
12
13
14
15 of the study.
16
17
18

19 **Were patients involved in the recruitment to and conduct of the study?**

20
21
22
23 In the first step of the study, the development of the first prototype, our patient
24
25
26
27 partner helped us to recruit patients by sharing the invitation through his personal
28
29
30
31 contacts and network and gave feedback for the pros and cons of the prototype
32
33
34
35 development. He was also invited to contribute in editing the paper and is
36
37
38
39 considered as a coauthor.
40
41
42

43 **How will the results be disseminated to study participants?**

44
45
46
47 To develop our dissemination strategy, we will review the results with the patient
48
49
50
51 partner and integrate his feedback to ensure that we presented the results in the
52
53
54
55 most effective way for the general populations. We will send a summary of the
56
57
58
59
60

1
2
3 research results to study participants who have provided their mailing address in
4
5
6
7 the consent form and we will also organise events for patients and citizen groups
8
9
10
11 and associations, such as outreach communications and scientific café.
12
13
14
15
16
17

18 **For randomised controlled trials, was the burden of the intervention assessed by**
19
20
21 **patients themselves?**
22
23
24
25
26
27
28
29

30 For this part of the study, participants will assess the burden of the intervention by
31
32
33 participating in focus groups.
34
35
36
37

38 Phase 2: Pilot cluster randomized clinical trial

39
40
41
42

43 The Phase 2 of the project will consist in a feasibility study based on a pilot cluster
44
45
46 randomized clinical trial (c-RCT). Given the nature of the intervention, patients with
47
48
49
50 chronic diseases are followed by a small team of primary care clinicians.
51
52
53

54 *Study setting*

55
56
57
58
59
60

1
2
3 The study will be conducted in two Family Medicine Groups (FMG) from the same
4
5
6
7 health region (in the province of Quebec) but covering distinct areas, they have
8
9
10
11 been selected as the clusters.
12
13

14 15 ***Eligibility criteria***

16
17
18
19
20 Patients with two or more targeted chronic diseases (diabetes, hypertension,
21
22
23
24 dyslipidemia) and who had three or more visits in the last 12 months will be eligible.
25
26

27
28 Majors whose incapacity has been recognized judicially are in exclusion criteria.
29
30

31 32 ***Intervention***

33
34
35
36
37 The intervention is the device CONCERTO+, a user-centered, multifunctional and
38
39
40
41 personalized eHealth platform. Both groups, Experimental and control have the
42
43
44
45 same features with regard to participants eligibility. Experimental group from FMG
46
47
48
49 1 will use CONCERTO+ application during 6 months. The Control group from FMG
50
51
52
53 2 will not use the application CONCERTO+ but continue to receive usual care. The
54
55
56
57
58
59
60

1
2
3 objective is to assess the feasibility, acceptability and potential effectiveness of the
4
5
6
7 device CONCERTO+.
8
9

10 11 *Outcomes*

12
13
14
15
16 The involvement of patients following the use of CONCERTO+ will be our primary
17
18
19
20 outcome of interest. We will use Patient Activation Measure (PAM) [52] which is
21
22
23
24 built on patient knowledge, skills and confidence that are directly targeted by the
25
26
27 intervention.
28
29

30
31
32 The score of the activation level obtained (between 0 and 100) shows the degree
33
34
35 of ability to manage their health with confidence according to the following scale
36
37
38 ranges: strongly disagree = 1; disagree = 2; agree = 3; strongly agree = 4. Patients
39
40
41
42 who are more activated have better health outcomes. Patients answer to a survey
43
44
45
46 of 13 questions with the following scoring for each answer:
47
48
49

- 50
51 1. Not believing that activation is important (≤ 47)
52
53
- 54
55 2. Lack of knowledge or confidence to take action (47.1 - 55.1)
56
57

1
2
3
4 3. Beginning to take action (55.2 - 67)
5
6
7

8 4. Taking action (≥ 67.1).
9
10

11
12 The PAM 13 questionnaire has been validated in French (see **Supplementary File**
13

14
15
16 3). We will ask a license to use, which is free for up to 250 patients in an academic
17
18
19
20 research context [53]. The survey will be completed by participants of the two
21
22
23
24 groups at baseline, and six months later. This period of CONCERTO+ use is
25
26
27
28 enough to achieve the intended outcomes.
29

30
31
32 Secondary outcomes of interest are: 1) the impact of CONCERTO+ use on process
33
34
35
36 indicators and care outcomes, measured with questions adapted from Glasgow et
37
38
39 al. [54] and validated in the previous Concerto Health Program (CHP) assessment;
40
41
42
43 Patients answer to a questionnaire after six months use of CONCERTO+. 5 scales
44
45
46
47 based on the key components of CONCERTO+ are defined, and each scale
48
49
50
51 include items: solving-problems/advices, delivery System design/decision support,
52
53
54
55 goal setting/tailoring, follow-up / coordination, overall care. Items are scored on a
56
57
58
59
60

1
2
3 5-point scale ranging from 1 (Almost never) to 5 (Almost always), passing through
4
5
6
7 subscales (Generally not); (Sometimes); Most of the time. Higher scores from the
8
9
10
11 assessment survey have better effects in care outcomes.
12

13
14
15 2) The acceptability of the device CONCERTO+ will be assessed by patient and
16
17
18 informal caregiver, at the end of the intervention with:
19
20

21
22
23 1. A short survey adapted from the Technology Acceptance Model [55] that
24
25
26 includes 3 criteria (perceived ease of use, perceived usefulness, behavioral
27
28
29 intention to use) with the following scoring: Strongly disagree = 1; Disagree = 2;
30
31
32 Agree = 3; strongly agree = 4. Higher scores rates have a better acceptance of
33
34
35 the use of CONCERTO+.
36
37
38

39
40
41
42 2. The use of CONCERTO+ that will be measured by logs (Tests numbers,
43
44
45
46 emergency visits, and hospitalizations). (See **Supplementary File 1, 3**).
47
48
49

50 *Participant timeline*

51
52
53
54
55
56
57
58
59
60

Table 1 shows the distribution of outcomes measures through time. The first survey

will be completed at baseline and six months after the use of CONCERTO+, in

Time point	Study period			
	Allocation out	Post allocation	Close	
	-T1	T1 (at baseline)	T2 (6 months after the use of Concerto+)	T3: During 3 months following the end of the intervention
Enrolment - Eligibility screen - informed consent - Allocation				
Intervention group	✓	✓	✓	✓
Usual care group	✓			
Assessments				
Main outcome measure PAM measure		✓	✓	
Secondary outcome measure			✓	

order to

see the

effects of

the use of

CONCERTO+ during the process care. The second survey will be completed six

months after in order to assess the effects of

Glasgow and al. Adapted survey				the use
Technology Acceptance Model		✓		and the
Logs measures		✓		third
Two Focus groups				survey will
Interviews			✓	be
			✓	completed

by patients and informal caregivers at the end of the intervention in order to assess the acceptability.

For peer review only

Sample size calculation

Based on a similar study [56], a sample of 200 patients is enough to detect a difference of 2 points on the PAM score, with a power of 90% and an alpha of 0.05.

Indeed, the assessment of online education intervention to chronic disease patients, showed a significant difference of 6 points on the PAM score in the experimental group (n = 58), whereas the difference was not significant in the control group (n = 68) [56]. Such a difference may be considered clinically significant because each additional point on the PAM score is associated with a 2% decrease in hospitalizations [53]. Considering an attrition rate of 15%, the sample size should remain relevant to detect a difference of at least 2 points on the PAM score, as differences reported in similar studies range from 2.5 to 6.5 points [14].

Recruitment strategy

1
2
3
4 For the first phase 1, the development of the eHealth solution module, we will
5
6
7 recruit 7 to 10 patients and informal caregivers from convenience samples of
8
9
10
11 volunteers joined through patient associations and mailing lists of our institution
12
13
14 (Université Laval-UL). Eligible individuals will meet the following criteria: 1) Have
15
16
17 two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) 2)
18
19
20 had three or more visits in the last 12 months; 3) aged 18 years old and over and
21
22
23 come from the greater Quebec area; 4) having in interest of technology; 5) be able
24
25
26 to speak and read in French; 6) available to participate in three validation sessions.
27
28
29
30
31
32

33
34 For the phase 2, the pilot cluster randomized clinical trial: a note will be added in
35
36
37 the EMR (electronic Medical Record) of patients who had been preselected, and
38
39
40
41 at their next visit at the FMG, the receptionist will give them an information sheet
42
43
44
45 about the study to invite them to participate. Interested patients will be invited to
46
47
48
49 call the research assistant using a toll free number or to leave their contact
50
51
52
53 information to the receptionist who will forward them to the research assistant.
54
55
56
57
58
59
60

1
2
3 Then, patients will be contacted by the research assistant to validate their eligibility
4
5
6
7 and confirm their interest. Recruitment will end when 100 patients are recruited
8
9
10
11 from each site. We will ensure an equal distribution of participants according to
12
13
14 their sex, and we will consider specific aspects in patient recruitment, particularly
15
16
17 living alone, the presence of dependents and their literacy level. The recruitment
18
19
20
21
22 chart is presented in **Fig. 2**
23
24
25

26 *Allocation*

27
28
29
30 Patient will be selected randomly with the help of the participating FMG by
31
32
33
34 searching the local EMR system. A pre-selection of patients will be done by the
35
36
37
38 four nurses involved in chronic disease care at the participating FMG. For each
39
40
41
42 site, a sample of 200 patients (see sample size calculation) stratified by sex, age
43
44
45
46 group and number of chronic diseases, will be randomly preselected by a
47
48
49
50 statistician not involved in the team, using a computerized program. Then, the
51
52
53
54 statistician will reveal group assignment through a call to the responsible of each
55
56
57
58
59
60

1
2
3 FMG in the presence of a research team member.
4
5
6
7

8 *Blinding* 9

10
11
12
13 The blinding will be single by the outcome assessor.
14
15

16 17 Phase 3: Scaling-up potential of the solution 18 19

20
21
22 For Phase 3, the analysis of CONCERTO+ potential for scaling-up will be done by
23
24
25 documenting factors and conditions associated with the sustainability and scaling-
26
27
28 up of the solution. To do so, we will conduct: 1) two focus groups with patients and
29
30
31 informal caregivers who participated in the study (1 with the experimental group
32
33
34 and 1 with the control group, each group gathering between 8 and 12 participants);
35
36
37
38 2) semi-structured individual interviews with health professionals as well as with
39
40
41 health care managers, information officers, and representatives of the Ministry of
42
43
44
45 Health and Social Services will be conducted at the two study sites two FMG of
46
47
48
49 one region in the Province of Quebec). The number of interviews will be determined
50
51
52
53
54
55
56
57
58
59
60

1
2
3 according to the data saturation principle, but is estimated to be around 15
4
5
6
7 participants in total. Interviews with patients, informal caregivers and health
8
9
10 professionals will include questions about factors facilitating or limiting sustained
11
12 use of the CONCERTO+ solution by patients and informal caregivers, and the
13
14 support of this use by health professionals, inspired by a recent study on personal
15
16 electronic health record [58, 59]. Questions for managers and decision-makers will
17
18 be based on Expand Net framework [60] that proposes 12 elements helping to
19
20 appreciate the potential of innovation expansion at different time of its progress
21
22
23
24
25
26
27
28
29
30
31
32
33
34 (see **Supplementary File 2,4**).

35 36 37 38 39 Data analysis plan

40
41
42
43
44 The study started in 2017 and will end in 2019. Data will be collected managed and
45
46
47 analysed at each step of the project. For the phase 1, we started to collect data in
48
49
50
51
52 October 2018; for the phase2, we will start in April 2019 and the phase 3 in
53
54
55
56
57
58
59
60 November 2019. We will ensure that surveys are correctly completed in order to

1
2
3 avoid many missing data. Quantitative data will be analyzed using standard
4
5
6
7 statistical model Anova, we will compare the scores test for repeated
8
9
10
11 measurements, controlling the initial PAM score. We will also make tests according
12
13
14 to sex, literacy level and comorbidity because these variables are associated with
15
16
17 the PAM score [57]. Focus groups discussions and interviews will be recorded with
18
19
20 participants' consent, and the content will be transcribed verbatim. The qualitative
21
22
23 analysis will consist in a thematic-pragmatic content analysis [61] using the NVivo
24
25
26 10 software. We will use an inductive-deductive analysis, in an iteratively and
27
28
29 flexible way, which allows a hybrid codification from the conceptual dimensions of
30
31
32 the model and the emergent themes [62]. We will verify the role of the identified
33
34
35 dimension in the literature as the initial basis for analysis, while remaining open to
36
37
38 the advent of other context-specific aspects. Results from qualitative analyses will
39
40
41 be cross with quantitative data to see commonalities among participants'
42
43
44 characteristics. The investigators will compare intervention and control groups to
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 judge the effectiveness of CONCERTO+ and will inform if there is an effect in their
4
5
6
7 health status. Participants will also be asked about the helpfulness of the device in
8
9
10
11 supporting their disease self-management.
12
13

14 15 Monitoring

16
17
18
19 A Data Monitoring Committee is not required for this study due to low risk of
20
21
22
23 adverse events. The principal investigator has the authority to suspend or terminate
24
25
26
27 the study at any time if any big trouble occurs.
28
29
30

31 32 Ethics and dissemination

33
34
35
36
37 This study has ethical approval from the Research Ethics Committee of Université
38
39
40
41 Laval; approval number: 2018-067 /01-06-2018 with all protocol modifications
42
43
44
45 being mandatory to report (see **Supplementary Files 5, 6**). All participants will
46
47
48
49 provide their consent following a procedure approved by the ethics board (see
50
51
52
53 **Supplementary Files 7-9**) before enrollment in the study. We have to communicate
54
55
56
57
58
59
60

1
2
3 with the ethics committee if any change occurs to the protocol. All data will be
4
5
6
7 anonymised and will be used only for statistical research and analysis. They will be
8
9
10
11 securely stored on the server of Canadian Research Chair on Technologies and
12
13
14 Practices in Health, we will never share it with third parties. Only the principal
15
16
17 investigator or his nominee and eventually students who work in the project will
18
19
20
21 have access on the list of participants in different phases of the project. Data from
22
23
24
25
26 EMR will be also anonymised by a medical secretary or a research assistant who
27
28
29
30 will sign a confidentiality agreement. In addition, all team members will sign a
31
32
33
34 confidentiality agreement so that any personal information of participants will not
35
36
37
38 be shared.
39
40

41
42 In keeping with our participative approach and inspired by frameworks of
43
44
45 collaboration between researchers and knowledge users [63, 64], knowledge
46
47
48
49 translation will be done in an integrated way throughout the project, with an
50
51
52
53 emphasis on collaboration, shared outcomes, and feedback from stakeholders at
54
55
56
57
58
59
60

1
2
3 each step of the research. We will also share the outcomes through presentations
4
5
6
7 in the networks and organizations of the team members, and through the
8
9
10 production of dissemination tools for patient and citizen groups and associations.
11
12
13 Ideally, these presentations will be done in tandem (patient-researcher; patient-
14
15 clinician) in an interactive way, by taking the time for discussion and exchanges
16
17
18 with the audience (e.g. lunch and learn, scientific café). The presentations will be
19
20
21 supported with materials (brief reports, narrated slideshows, etc.) allowing a
22
23
24 greater dissemination of the activities and outcomes. Knowledge translation
25
26
27 activities at the end of project will consist of publishing outcomes in open access /
28
29
30 peer reviewed journals. Presentations at national and international conferences in
31
32
33 health informatics, chronic diseases, and patient engagement are also scheduled.
34
35
36
37
38
39
40
41
42
43
44

45 Study status

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 This is an ongoing study taking place from December 2017 until December 2019.
4
5
6

7 At the time of writing, the prototype of the eHealth technology module was designed
8
9
10
11 and the first usability test is done.
12
13
14

15 Discussion

16
17
18
19
20
21 This project shows a potential of success through the involvement of the
22
23
24
25 technological partner who has a long collaborative experience with researchers.
26
27

28
29 The eHealth solution is also likely to be acceptable because it will be adapted to
30
31
32 patient's needs, based on our user-centered approach and the adaptation of the
33
34
35
36 content to users' literacy level. Previous results associated with the use of the CHP
37
38
39
40 solution for clinicians show promising preliminary outcomes based on validated
41
42
43
44 measures that are relevant and sensitive to the proposed intervention. The solution
45
46
47
48 has also a good potential for sustainability given that it will be implemented in the
49
50
51
52 real context of primary care practice, with the collaboration of clinical teams. Finally,
53
54
55
56 the project team is engaged in disseminating the results and pursuing the
57
58
59
60

1
2
3 development and adaptation of the CONCERTO+ solution in order to contribute to
4
5
6
7 improving the health of people in Canada and internationally.
8
9
10
11
12
13
14
15

16 List of abbreviations

17
18
19
20
21 **CHP:** Concerto Health Program
22
23

24
25
26 **c-RCT:** cluster randomized clinical trial
27
28

29
30 **EMR:** Electronic Medical Record
31
32

33
34 **FMG:** Family medicine Group
35
36

37
38 **IT:** Information Technology
39
40

41
42 **PAM:** Patient activation measure
43
44

45
46
47 **PICO:** Problem, Intervention, Comparison-Outcomes
48
49

50
51 **SPOR:** Strategy of Patient-Oriented Research
52
53

54
55 **UL:** Université Laval
56
57

References

1. World Health Organization. WHO - Global status report on noncommunicable diseases. 2014.
http://apps.who.int/iris/bitstream/handle/10665/148114/9789241564854_eng.pdf.
2. Roberts KC, Rao DP, Bennett TL, Loukine L, Jayaraman GC. Prevalence and patterns of chronic disease multimorbidity and associated determinants in Canada. *Health Promot Chronic Dis Prev Can*. 2015;**35**:87-94.

- 1
2
3
4 3. Health Council of Canada. Helping patients help themselves: are Canadians
5
6
7 with chronic conditions getting the Support they need to manage their
8
9
10
11 health? 2010. [https://healthcouncilcanada.ca/files/2.17-](https://healthcouncilcanada.ca/files/2.17-AR1_HCC_Jan2010.pdf)
12
13
14
15 AR1_HCC_Jan2010.pdf
16
17
18
19
20
21
22
23 4. Ruel, G. (2012). Multimorbidité : Ampleur, impacts et défi. In: *4e Rendez-*
24
25
26 *vous des maladies chroniques*. Quebec: Institut national de santé publique
27
28
29
30
31 du Québec (accessed 28 Apr 2017).
32
33
34
35
36
37
38
39
40
41 5. Fortin M, Contant E, Savard C, Hudon C, Poitras M-E, Almirall J. Canadian
42
43
44 guidelines for clinical practice: an analysis of their quality and relevance to
45
46
47
48 the care of adults with comorbidity. *BMC Fam Pract*. 2011;**12:74**.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 6. Bounajm F, Dinh T, Thériault L: Améliorer les habitudes de vie: des
5
6
7 retombées importantes pour la santé et l'économie du Québec. 2017.
8
9
10
11 <https://www.conferenceboard.ca/temp/7230eaa9-bb8f-43ae-8ecb>
12
13
14 969e71c8c696/6647_SanteEtEconomieDuQuebec_RPT.pdf (accessed 29
15
16
17
18 May 2018).
- 19
20
21
22
23
24
25
26 7. The Commissaire à la Santé et au Bien-Être. Adopting an integrated
27
28
29 approach to chronic disease prevention and management:
30
31
32
33 recommendations, issues and implications, 2010.
34
35
36
37 <https://www.csbe.gouv.qc.ca/fileadmin/www/2010/MaladiesChroniques/CSB>
38
39
40
41 E_T4_Recommandations2010.pdf
42
43
44
45
46
47
48
49
50
51 8. Ministère de la Santé et des Services Sociaux. Cadre de référence pour la
52
53
54
55 prévention et la gestion des maladies chroniques physiques en première
56
57
58
59
60

1
2
3 ligne.2012. <http://publications.msss.gouv.qc.ca/msss/fichiers/2012/12-942->

4
5
6
7 [01F.pdf](#)
8
9
10
11
12
13
14
15
16

17 9. FMOQ, The Fédération des médecins omnipraticiens du Québec.
18

19
20
21 Communiqué de la FMOQ: La FRMOQ lance une nouvelle campagne
22

23
24 publicitaire pour rappeler l'urgence d'investir en médecine familiale. (2011)
25
26

27
28 Montréal.
29
30
31
32
33
34
35

36 10. Bates-Eamer N, JL Ronson. Perceived shortage, relative surplus: the
37

38
39 paradox of Quebec's Family physician workforce - An Intra- and
40
41

42
43 Inter-Provincial Comparison, U.o.V. Centre for Global Studies, Editor. 2009.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 11. OCDE, The Organization for Economic Co-operation and Development:
5
6
7 Promoting health, preventing disease, the economic case.
8
9
10
11 <https://www.oecd-ilibrary.org/docserver/9780335262274->
12
13
14 [en.pdf?expires=1535485524&id=id&accname=guest&checksum=37E5F5C](https://www.oecd-ilibrary.org/docserver/9780335262274-en.pdf?expires=1535485524&id=id&accname=guest&checksum=37E5F5C0D17CCC858CBF41B9E570C708)
15
16
17
18 0D17CCC858CBF41B9E570C708. In The European Observatory on Health
19
20
21
22 Systems and Policies Series (2015). Accessed 28 August 2018.
23
24
25
26
27
28
29
30
31
32 12. Adams SG, Smith PK, Allan PF, Anzueto A, Pugh JA, Cornell JE.
33
34
35
36 Systematic Review of the Chronic Care Model in Chronic Obstructive
37
38
39
40 Pulmonary Disease Prevention and Management. Arch Intern Med. 2007;
41
42
43 167:551-61. doi:10.1001/archinte.167.6.551
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 13. Longtin Y, Sax H, Leape LL, Sheridan SE, Donaldson L, Pittet D. Patient
5
6
7 participation: current knowledge and applicability to patient safety Mayo Clin
8
9
10
11 Proc. Elsevier. 2010 January;85:53-62.
12
13
14
15
16
17
18
19
20
21 14. Hibbard JH, Greene J. What the evidence shows about patient activation:
22
23
24 better health outcomes and care experiences; fewer data on costs. Health
25
26
27
28 affairs. 2013;32:207-214.
29
30
31
32
33
34
35
36
37
38 15. Greene J, Hibbard JH. Why does patient activation matter? An examination
39
40
41
42 of the relationships between patient activation and health-related outcomes.
43
44
45
46 J Gen Intern Med. 2012; 27:520-6.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 16. Hibbard JH, Mahoney E R, Stock R, Tusler, M. Do increases in patient
5
6
7 activation result in improved self-management behaviors?. Health Services
8
9
10
11 Research.2007;42:1443-63.
12
13
14
15
16
17
18
19
20
21 17. Fowles JB, Terry P., Xi M, Hibbard J, Bloom CT, Harvey L. Measuring self-
22
23
24 management of patients' and employees' health: further validation of the
25
26
27 Patient Activation Measure (PAM) based on its relation to employee
28
29 characteristics. Patient Educ Couns. 2009;77:116-22
30
31
32
33
34
35
36
37
38
39
40
41
42 18. Mosen DM, Schmittdiel J, Hibbard J, Sobel D, Remmers C, Bellows J. Is
43
44
45 patient activation associated with outcomes of care for adults with chronic
46
47
48 conditions? J Ambul Care Manage. 2007;30:21.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 19. Becker ER, Roblin D W. Translating primary care practice climate into
5
6
7 patient activation: the role of patient trust in physician. Med care.
8
9
10
11 2008;**46**:795-805.
12
13
14
15
16
17
18
19
20
21 20. Hibbard JH, Cunningham PJ. How engaged are consumers in their health
22
23
24 and health care, and why does it matter? Res Briefs. 2008;**8**:1-9.
25
26
27
28
29
30
31
32
33
34
35 21. Remmers C, Hibbard J, Mosen DM, Wagenfield M, Hoyer RE, Jones C. Is
36
37
38 patient activation associated with future health outcomes and health-care
39
40
41 utilization among patients with diabetes? J Ambul Care
42
43
44
45 Manage.2009;**32**:320-7.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 22. Donald M, Ware RS, Ozolins IZ, Begum N, Crowther R, Bain C. The role of
5
6
7 patient activation in frequent attendance at primary care: a population-
8
9
10
11 based study of people with chronic disease. *Patient Educ Couns*.
12
13
14
15 2011;**83**:217-21.
16
17
18
19
20
21
22
23
24 23. Greene J, Hibbard JH, Sacks R, Overton V, Parrotta CD. When patient
25
26
27 activation levels change, health outcomes and costs change, too. *Health*
28
29
30
31
32 affairs. 2015;**34**:431-7.
33
34
35
36
37
38
39
40
41
42 24. Holmström I, Röing M. The relation between patient-centeredness and
43
44
45
46 patient empowerment: a discussion on concepts. *Patient Educ Couns*.
47
48
49
50 2010; **79**:167-72.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 25. Pomey MP, Flora, L, Karazivan P, Dumez V, Lebel P, Vanier MC., et al. Le
5
6
7 "Montreal model" : enjeux du partenariat relationnel entre patients et
8
9
10
11 professionnels de la sante. Sante Publique.2015; **HS**:41-50.
12
13
14
15
16
17
18
19
20
21 26. Kickbusch I, Pelikan J, Apfel F, Tsouros A. Health literacy. World Health
22
23
24 Organisation 2013.
25
26
27
28 http://www.euro.who.int/__data/assets/pdf_file/0008/190655/e96854.pdf.
29
30
31
32
33
34
35
36 27. Hart JT. The Autonomous Patient: Ending Paternalism in Medical
37
38
39
40 Care.JRSM.2002; **95**:623-4.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 28. Koh H.K, Brach C, Harris LM, Parchman ML. A proposed 'health literate
5
6
7 care model' would constitute a systems approach to improving patients'
8
9
10 engagement in care. Health Affairs.2013;**32**:357-67.
11
12
13
14
15
16
17
18
19
20
21 29. Frosch DL, Elwyn G. Don't blame patients, engage them: transforming
22
23
24 health systems to address health literacy. Journal of health
25
26
27 communication.2014;**19**:10-4.
28
29
30
31
32
33
34
35
36 30. Monkman H, Andre W. eHealth literacy issues, constructs, models, and
37
38
39 methods for health information technology design and evaluation.
40
41
42 Knowledge Management & ELearning: An International Journal
43
44
45
46
47 (KM&EL).2015;**7**: 541-9.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 31. Chaudhry B, Wang J, Wu S, Maglione M, Mojica W, Roth E, Shekelle PG.
5
6
7 Systematic review: impact of health information technology on quality,
8
9
10
11 efficiency, and costs of medical care. *Annals of Internal*
12
13
14
15 *Medicine*.2006;**144**:742-52.
16
17
18
19
20
21
22 32. Cummings E, Turner P. Patient self-management and chronic illness:
23
24
25
26 evaluating outcomes and impacts of information technology. *Studies in*
27
28
29
30 *health technology and informatics*.2008;**143**:229-34.
31
32
33
34
35
36
37
38
39
40 33. Dorr D, Bonner LM, Cohen, AN, Shoai, RS, Perrin R, Chaney E, Young AS.
41
42
43
44 Informatics systems to promote improved care for chronic illness: a
45
46
47
48 literature review. *JAMIA*. 2007;**14**:156-63.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 34. Häyrinen K, Saranto K, Nykänen P. Definition, structure, content, use and
5
6
7 impacts of electronic health records: a review of the research literature. Int J
8
9
10
11 Med Inform. 2008;**77**:291-304.
12
13
14
15
16
17
18
19
20
21 35. Lau F, Kuziemyky C, Price M, Gardner JA. Review on systematic reviews
22
23
24 of health information system studies. JAMIA. 2010;**17**:637-45.
25
26
27
28
29
30
31
32
33
34 36. Rigby M, Georgiou A, Hyppönen H, Ammenwerth E, de Keizer N, Magrabi
35
36
37
38 F, Scott P. Patient Portals as a Means of Information and Communication
39
40
41
42 Technology Support to Patient-Centric Care Coordination – the Missing
43
44
45
46 Evidence and the Challenges of Evaluation. Yearbook of Medical
47
48
49 Informatics 2015;**10**:148-59.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 37. Eland-de Kok, Pvan Os-Medendorp H, Vergouwe-Meijer A,
5
6
7 Bruijnzeel-Koomen C, Ros W. A systematic review of the effects of e-health
8
9
10
11 on chronically ill patients. J ClinNurs, 2011;**20**:2997-3010.
12
13
14
15
16
17
18
19
20
21 38. Irizarry T, Dabbs AD, Curran CR. Patient portals and patient engagement:
22
23
24 a state of the science review. JMIR. 2015;**17**.
25
26
27
28
29
30
31
32
33
34 39. Price M, Bellwood P, Kitson N, Davies I, Weber J, Lau F. Conditions
35
36
37
38 potentially sensitive to a personal health record (PHR) intervention, a
39
40
41
42 systematic review. BMC Med Inform Decis Mak. 2015;**15**:32.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 40. Ross J, Stevenson F, Lau R, Murray E. Factors that influence the
5
6
7 implementation of e-health: a systematic review of systematic reviews (an
8
9
10
11 update). *Implementation Science*. 2016;**11**:146.
12
13
14
15
16
17
18
19
20
21 41. Strisland F, Svagård ., Austad H, Reitan J. Meeting end user needs in
22
23
24 international research projects aiming to develop medical device technology
25
26
27
28 prototypes for integrated care: A case study. *Int J Integr Care* 2016;**16**.
29
30
31
32
33
34
35
36
37
38 42. Monkman H, KUSHNIRUIC A. Applying usability methods to identify health
39
40
41
42 literacy issues: an example using a Personal Health Record. *Stud Health*
43
44
45
46 *Technol Inform*. 2013; 183:179-85.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 43. Research2Guidance. mHealth App Developer Economics: The current
5
6
7 status and trends of the mHealth app market, 2017.
8

9
10
11 [https://www.uzelf.org/wp-content/uploads/2017/12/R2G-mHealth-
12
13
14
15 Developer-Economics-2017-Status-And-Trends.pdf](https://www.uzelf.org/wp-content/uploads/2017/12/R2G-mHealth-Developer-Economics-2017-Status-And-Trends.pdf)
16
17

- 18
19
20
21
22
23
24 44. Greenhalgh T, Hinder S, Stramer K, Bratan T, Russell J. Adoption, non-
25
26
27 adoption, and abandonment of a personal electronic health record: case
28
29
30
31
32 study of HealthSpace. *BMJ*. 2010;**341**:c5814.
33
34

- 35
36
37
38
39
40
41
42 45. Garabedian, LF, Ross-Degnan, D, Wharam JF. Mobile phone and
43
44
45
46 smartphone technologies for diabetes care and self-management. *Current*
47
48
49
50 diabetes reports. 2015;**15**:109.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 46. Group N. Catalyst Insights Council Monthly Report: How to Hardwire Patient
5
6
7 Engagement into Care Delivery Processes, 2017.
8

9
10
11 <https://join.catalyst.nejm.org/hubfs/Insights%20Council%20Monthly%20->

12
13
14 %20Files/Insights%20Council%20Monthly%20May%202017%20Report_Ho

15
16
17 w%20to%20Hardwire%20Patient%20Engagement%20into%20Care%20Del

18
19
20
21
22 ivery%20Processes.pdf.
23
24
25
26
27
28
29

- 30 47. Khoja S, Durrani H, Scott RE, Sajwani A, Piryani U. Conceptual framework
31
32
33 for development of comprehensive e-health evaluation tool. *Telemedicine*
34
35
36 and e-Health. 2013;**19**:48-53.
37
38
39
40
41
42
43
44
45
46

- 47 48. Lawani MA, Valéra B, Fortier-Brochu É, Légaré F, Carmichael PH, Côté L,
48
49
50
51 Giguere AM. Five shared decision-making tools in 5 months: use of rapid
52
53
54
55
56
57
58
59
60

1
2
3 reviews to develop decision boxes for seniors living with dementia and their
4
5
6
7 caregivers. *Systematic reviews*. 2017;**6**:56.
8
9

- 10
11
12
13
14
15
16
17 49. Zanaboni P, Ngangue P, Mbemba GIC, Schopf TR, Bergmo TS, Gagnon M
18
19
20
21 P. Methods to Evaluate the Effects of Internet-Based Digital Health
22
23
24 Interventions for Citizens: Systematic Review of Reviews. *JMIR*.
25
26
27
28 2018;**20**e10202.
29
30

- 31
32
33
34
35
36
37
38 50. Giguere AM, Labrecque M, Haynes RB, Grad R, Pluye P, Légaré F, et al.
39
40
41
42 Evidence summaries (decision boxes) to prepare clinicians for shared
43
44
45
46 decision-making with patients: a mixed methods implementation study.
47
48
49
50 Implement Sci.2014;**9**:144.
51
52
53
54
55
56
57
58
59
60

1
2
3 51. Lemieux V. Pour qu'on se comprenne: guide de littérature en santé, 2014.

4
5
6
7 https://publications.santemontreal.qc.ca/uploads/tx_asssmpublications/litter
8
9
10
11 [atie_v9.pdf](#).

12
13
14
15
16
17
18 52. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing
19
20
21
22 of a short form of the patient activation measure. Health Services
23
24
25
26 Research.2005;40:1918-30.

27
28
29
30
31
32
33
34
35
36 53. Health I. Patient Activation Measure, 2014. <http://www.insigniahealth.com/>

37
38
39
40
41
42
43 54. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM.
44
45
46
47 Development and validation of the patient assessment of chronic illness
48
49
50
51 care (PACIC). Medical care. 2005:436-44.

- 1
2
3
4
5
6
7
8
9 55. Davis FD. Perceived usefulness, perceived ease of use, and user
10
11
12 acceptance of information technology. MIS quarterly.1989:319-40.
13
14
15
16
17
18
19
20
21
22 56. Solomon M, Wagner SL, Goes J. Effects of a Web-based intervention for
23
24
25 adults with chronic conditions on patient activation: online randomized
26
27
28
29 controlled trial. JMIR. 2012;**14**:e32.
30
31
32
33
34
35
36
37
38
39 57. Hendriks M, Rademakers J. Relationships between patient activation,
40
41
42
43 disease-specific knowledge and health outcomes among people with
44
45
46
47 diabetes; a survey study. BMC health serv res. 2014;**14**:393.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 58. Ghandour E, Gagnon M-P, Fortin J-P. Patient adoption of a connected
4
5
6
7 electronic personal health record to support chronic disease management in
8
9
10
11 primary care in Quebec. Submitted for publication.
12
13

14
15
16
17
18
19
20
21 59. Ghandour E, Gagnon M-P, Fortin J-P. Conditions d'adoption du dossier de
22
23
24 santé électronique personnel par les professionnels de la première ligne au
25
26
27
28 Québec : Perspectives professionnelle et organisationnelle. Revue Santé
29
30
31 Publique. 2017; 29:837-850.
32
33
34

35
36
37
38
39
40 60. World Health Organization. Beginning with the end in mind planning pilot
41
42
43 projects and other programmatic research for successful scaling up, 2014.
44
45
46
47 [http://apps.who.int/iris/bitstream/handle/10665/44708/9789241502320_eng.](http://apps.who.int/iris/bitstream/handle/10665/44708/9789241502320_eng.pdf)
48
49
50
51 [pdf.](http://apps.who.int/iris/bitstream/handle/10665/44708/9789241502320_eng.pdf)
52
53
54
55
56
57
58
59
60

- 1
2
3
4 61. Aronson J. A pragmatic view of thematic analysis. Qualitative
5
6
7 Report.1994;2:1-3
8
9
10
11
12
13
14
15
16
17 62. Miles MB, Huberman AM. Qualitative data analysis: An Expanded
18
19
20 Sourcebook. Sage. 2003.
21
22
23
24
25
26
27
28
29
30
31 63. Parry D, Salsberg J, Macaulay AC, et al. A Guide to Researcher and
32
33
34 Knowledge-User Collaboration in Health Research. C.I.o.H.R. (CIHR)
35
36
37 Editor. 2009:83.
38
39
40
41
42
43
44
45
46
47
48 64. Baumbusch JL, Kirkham SR, Khan KB, McDonald H, Semeniuk P, Tan E,
49
50
51
52 Anderson JM. Pursuing common agendas: a collaborative model for
53
54
55
56
57
58
59
60

1
2
3 knowledge translation between research and practice in clinical settings.
4
5
6

7 Res Nurs Health. 2008; 31:130-40.
8
9
10

11 Footnotes

12
13
14
15
16
17

18 **Protocol version:** Version 1 (November 15th 2018)
19
20
21

22 **Funding:** This study is funded by Canadian Institutes of Health Research.
23
24
25

26 **Funding Reference Number:** PCG-155469 (see **Supplementary File 10**).
27
28
29

30 **Authors' contributions:** MPG, AL, GC, and CC conceived and designed the study
31
32
33

34 and drafted the manuscript. AG, JPF, FL, HW, ALB, RB, CS, AM, SRA, CD, EK,
35
36
37

38 FLP, JR, MAN participated in designing the study and revised the manuscript. All
39
40
41

42 authors read and approved the final manuscript.
43
44
45

46 **Competing interest:** The authors declare that they have no competing interests.
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 1 Embedded Healthcare System

Phase 1



Phase 2



Phase 3




Figure 2 Recruitment flowchart

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

Supplementary File 1: Outcome measures and items (original English version)

1. Patient Activation
Tool used
<i>Patient Activation Measure-PAM-13</i>
Criteria¹
1. When all is said and done, I am the person who is responsible for managing my health condition. 2. Taking an active role in my own healthcare is the most important factor in determining my health and ability to function. 3. I am confident that I can take actions that will help prevent or minimize some symptoms or problems associated with my health condition. 4. I know what each of my prescribed medications does. 5. I am confident I can tell when I need to go get medical care and when I can handle a health problem. 6. I am confident I can tell my health provider the concerns I have even when he or she does not ask. 7. I am confident I can follow through on the medical treatment I need to do at home. 8. I understand the nature and causes of my health condition. 9. I know the different medical treatment options available for my health condition. 10. I have been able to maintain the lifestyle changes I have made for my health. 11. I know how to prevent further problems with my health condition. 12. I am confident I can find a solution when new situations or problems arise with my health condition. 13. I am confident I can maintain lifestyles changes, like diet and exercise, even during times of stress.
Results measurement
Scoring (for each criteria): <ul style="list-style-type: none"> ▪ Strongly disagree = 1 ▪ Disagree = 2 ▪ Agree = 3 ▪ Strongly agree = 4
Activation level (converted into a score of 100): <ol style="list-style-type: none"> 1. Not believing that activation is important (≤ 47) 2. Lack of knowledge or confidence to take action (47.1-55.1) 3. Beginning to take action (55.2-67) 4. Taking action (≥ 67.1)

53
54
55
56
57
58
59
60

¹ Adapted from: Moljord I E O, Lara-Cabrera ML. Perestelo-Pérez L, Rivero-Santana A, Eriksen L, Linaker OM. Psychometric properties of Patient Activation Measure-13 among out-patients waiting for mental health treatment: a validation study in Norway. *Patient education and counseling*. 2015;98(11):1410-1417.

2. Impacts of the use of CONCERTO+

Tool used

Survey used for the assessment of the CHP pilot

Criteria¹

Problem-solving/Advice

1. Have you been asked how your illness affects your life?
2. Have you been helped in planning ahead to take care of your illness even in hard times?
3. Did your care providers ask about your values and traditions when they recommended treatment?
4. Have you been helped in drawing up a treatment plan that you could follow in your daily life?

Delivery system design/Decision support

1. Have you been asked about your health habits?
2. Have you been encouraged to go to a specific group or class to help you cope with your chronic illness?
3. Have you been given a copy of your treatment plan?

Goal-setting/Tailoring

1. Have you been asked to talk about your goals in the context of receiving care for your chronic condition?
2. Have you been helped in setting specific goals to improve your diet or fitness?
3. Have you been given a written list of things you should do to improve your health?
4. Have you been shown how taking proper care of your illness influenced your condition?
5. Are you satisfied that your care was well organized?

Follow-up/Coordination

1. Have you been referred to a dietitian, health educator, or counselor?
2. Have you been told how your visits with other doctors were going?
3. Have you been told how your visits with other types of doctors, such as a specialist or a surgeon, helped in your treatment?
4. Have you been asked how your visits with other doctors were going?
5. Have you been contacted after a visit to see how things were going?

Overall care²

Since you began using CONCERTO+

1. Have you had an appointment with a professional from the clinic?
2. Have you received help when you were in need?
3. Have you had a follow-up appointment for your health condition?
4. Have you been helped through contact with a professional from the team or by receiving an answer from one of the team members after a phone call?
5. Have you had the feeling that your nurse coordinates all of your care?
6. Have you had the feeling that your health problems are being taken into account by the Program team?
7. Have you noticed that your visits with other health professionals are being taken into account by the Program team?
8. Have you been helped in understanding your test results (e.g. laboratory test, pressure tap, etc.)?
9. Have you received an answer in emergency situations?

¹ These criteria were originally developed and validated by Glasgow RE, Wagner EW, Schaefer J, Mahoney LD, Reid RJ, Greene SM. 2005. Development and validation of the patient assessment of chronic illness care (PACIC). *Medical Care*. 43, 5: 436–444.

² Adapted from McIntosh, CN. Examen de la validité factorielle de certains modules de l'Enquête canadienne sur l'expérience des soins de santé primaires. Statistique Canada, Division de l'information et de la recherche sur la santé. July 2008.

3. Acceptance of CONCERTO+

Tool used

Survey based on the *Technology Acceptance Model*

Criteria

Perceived ease of use

1. My interaction with CONCERTO+ is clearer and more comprehensive.
2. I find it is easy to get CONCERTO+ to do what I want it to do.
3. The use of CONCERTO+ will improve my follow-up.
4. The use of CONCERTO+ will improve the effectiveness of my care.

Perceived usefulness

1. The use of CONCERTO+ will improve my health condition.
2. I find CONCERTO+ to be a useful tool for the follow-up of my health condition.
3. The use of CONCERTO+ is interesting.
4. I like to use a smart phone or a tablet to look for health information.
5. I'm eager to use technology to manage my health condition.

Behavioural intention to use

1. I'm going to use CONCERTO+ in the future.
2. Using CONCERTO+ is part of my plan.

4. The use of CONCERTO+

Tool used

CONCERTO+ logs use

Criteria

Logs

Supplementary File 2: ExpandNet recommendations for scaling up (WHO, 2013) Original English version

1. Engage in a participatory process involving key stakeholders.
2. Ensure the relevance of the proposed innovation.
3. Reach a consensus on expectations for scale up.
4. Tailor the innovation to the socio-cultural and institutional settings.
5. Keep the innovation as simple as possible.
6. Test the innovation in the variety of socio-cultural and institutional settings where it will be scaled up.
7. Test the innovation under routine operating conditions and existing resource constraints of the health system.
8. Develop plans to assess and document the process of implementation.
9. Advocate with donors and other sources of funding for financial support beyond the pilot stage.
10. Prepare to advocate for necessary changes in policies, regulations, and other health systems components.
11. Develop plans for how to promote learning and disseminate information.
12. Plan on being cautious about initiating scale up before the required evidence is available.

Supplementary File 3: Mesure d'activation du patient (PAM-13) French translation

1. Activation du patient	
Outil utilisé	
Mesure d'activation du patient (<i>Patient Activation Measure-PAM-13</i>)	
Critères ¹	
1.	En fin de compte, je suis la personne qui est responsable de gérer ma condition de santé
2.	Prendre un rôle actif dans mes soins de santé et le facteur le plus important pour déterminer ma santé et mon habileté pour fonctionner
3.	Je suis confiant que je peux prendre des actions qui m'aideront à prévenir ou minimiser certains symptômes ou problèmes associés avec ma condition de santé
4.	Je sais quels sont les effets de tous mes médicaments prescrits
5.	Je suis persuadé que je peux savoir quand j'ai besoin de soins médicaux et quand je peux gérer mes problèmes de santé par moi-même
6.	Je suis persuadé que je peux exprimer à mon professionnel de la santé mes préoccupations même quand il ou elle ne le demande pas
7.	Je suis convaincu que je peux appliquer les traitements médicaux dont j'ai besoin à la maison
8.	Je comprends la nature et les causes de ma condition de santé
9.	Je connais les différentes options de traitements médicaux qui sont disponibles pour ma condition de santé
10.	J'ai été capable de maintenir des changements de style de vie que j'ai adopté pour ma santé
11.	Je sais comment prévenir des problèmes ultérieurs en lien avec ma condition de santé
12.	Je suis confiant que je peux trouver des solutions quand des nouvelles situations ou problèmes apparaissent en lien avec ma condition de santé
13.	Je suis persuadé que je peux maintenant des changements de style de vie comme une diète et de l'exercice même durant des périodes de stress
Mesure des résultats	
Notation (pour chaque critère) :	
▪	Fortement en désaccord (1 point)
▪	En désaccord (2 points)
▪	En accord (3 points)
▪	Fortement en accord (4 points)
Niveaux d'activation (selon la conversion des résultats sur un score de 100) :	
1.	Ne croit pas que l'activation est important (≤ 47)
2.	Manque de savoir ou de confiance pour agir (47.1-55.1)
3.	Commence à agir (55.2-67)
4.	Agit (≥ 67.1)

¹ Adapté de: Moljord I E O, Lara-Cabrera ML, Perestelo-Pérez L, Rivero-Santana A, Eriksen L, Linaker OM. Psychometric properties of Patient Activation Measure-13 among out-patients waiting for mental health treatment: a validation study in Norway. *Patient education and counseling*. 2015;98(11):1410-1417.

Traduction libre

2. Impacts de l'utilisation de CONCERTO+

Outil utilisé

Questionnaire utilisé lors de l'évaluation de la phase pilote du Programme de santé Concerto ¹

Critères ²

Résolution de problèmes/conseils :

1. Vous a-t-on demandé quels étaient les effets de votre maladie sur votre vie ?
2. Vous a-t-on aidé à planifier afin de pouvoir prendre soin de votre état de santé même en des moments difficiles ?
3. Vos fournisseurs de soins tenaient-ils compte de vos valeurs et de vos traditions au moment de vous recommander un traitement ?
4. Vous a-t-on aidé à élaborer un plan de traitement que vous pourriez mettre en pratique dans votre vie quotidienne ?

Prestation de soins/aide à la décision :

1. Vous a-t-on posé des questions sur vos habitudes de santé ?
2. Vous a-t-on encouragé à faire partie d'un groupe ou d'une classe, comme une session d'information éducative, pour vous aider à vivre avec votre état de santé chronique ?
3. Vous a-t-on remis une copie de votre plan de traitement ?

Établissement des objectifs/personnalisation :

1. Vous a-t-on demandé de parler de vos objectifs en ce qui concerne la manière de prendre soin de votre condition chronique ?
2. Vous a-t-on aidé à fixer des objectifs spécifiques pour améliorer votre alimentation ou votre activité physique ?
3. Vous a-t-on montré comment ce que vous avez fait pour prendre soins de vous-même a influencé votre condition chronique ?
4. Vous a-t-on remis une liste écrite des choses que vous devriez faire pour améliorer votre santé ?
5. Étiez-vous satisfait de la manière dont vos soins étaient organisés ?

Coordination des soins :

1. Vous a-t-on dirigé vers un diététiste, un éducateur en matière de santé ou un conseiller ?
2. Vous a-t-on dit comment vos visites chez d'autres genres de médecins (p. ex., spécialiste, chirurgien) contribuaient à votre traitement ?
3. Vous a-t-on demandé comment se passaient vos visites chez les autres médecins ?
4. A-t-on communiqué avec vous après une visite pour savoir comment les choses se passaient ?

Globalité des soins :

Depuis que vous utilisez CONCERTO+, avez-vous...

1. Pu obtenir un rendez-vous avec un professionnel de la clinique ?
2. Été aidé(e) lorsque vous en aviez besoin ?
3. Obtenue un rendez-vous de suivi de votre condition de santé ?
4. Eu besoin d'entrer en contact avec un professionnel de l'équipe ou reçu une réponse de l'un d'entre eux à la suite de votre appel téléphonique ?
5. L'impression que votre infirmière coordonne l'ensemble de vos soins ?

¹ Adapté de : McIntosh, CN. Examen de la validité factorielle de certains modules de l'Enquête canadienne sur l'expérience des soins de santé primaires. Statistique Canada, Division de l'information et de la recherche sur la santé. Juillet 2008.

² Ces critères ont été développés initialement et validés par Glasgow et collaborateurs : Glasgow RE, Wagner EW, Schaefer J, MahoneyLD, Reid RJ, Greene SM. 2005. Development and validation of the patient assessment of chronic illness care (PACIC). Medical Care. 43, 5: 436-444.

6. Le sentiment que l'équipe du Programme a tenu compte de votre problème de santé ?
7. Pu constater que l'on a tenu compte de vos consultations avec d'autres professionnels de la santé que ceux de l'équipe du Programme ?
8. Pu vous faire aider à comprendre vos résultats de tests (par exemple : test de laboratoire, prise de pression, etc.) ?
9. Obtenue une réponse lors d'une situation urgente pour vous ?

3. Acceptation de CONCERTO+

Outils utilisé

Questionnaire basé sur le Modèle d'acceptation de la technologie

Critères

Facilité d'utilisation perçue :

1. Mon interaction avec le système CONCERTO+ est claire et compréhensible
2. Je trouve qu'il est facile de demander au système CONCERTO+ de faire ce que je veux
3. L'utilisation de CONCERTO+ améliorera mon suivi
4. L'utilisation de CONCERTO+ améliorera mon efficacité à me prendre en charge

Utilité perçue :

1. L'utilisation de CONCERTO+ améliorera mon état de santé
2. Je trouve que CONCERTO+ est un outil utile pour le suivi de mon état de santé
3. L'utilisation de CONCERTO+ plus intéressant.
4. J'aime travailler avec l'ordinateur.
5. Je cherche des aspects de mon métier qui demande d'utiliser l'ordinateur

Intention comportementale d'utiliser :

1. Je vais utiliser CONCERTO+ dans le futur.
2. J'établis un plan pour utiliser CONCERTO+

4. Utilisation de CONCERTO+

Outil utilisé

Registres d'utilisation de CONCERTO+

Critères

Registres (*Logs*)

Supplementary File 4:Recommandations d'ExpandNet pour le passage à l'échelle (OMS, 2013) (French translation)

1. Engager un processus participatif impliquant les principales parties prenantes
2. Assurer la pertinence de l'innovation proposée
3. Trouver un consensus sur les attentes à propos du passage à grande échelle
4. Ajuster l'innovation aux cadres socioculturels et institutionnels
5. Garder l'innovation aussi simple que possible
6. Tester l'innovation dans la variété de cadres socioculturels et institutionnels où elle passera à grande échelle
7. Tester l'innovation dans les conditions de fonctionnement de routine et sous les contraintes de ressource actuelles du système de santé
8. Planifier l'évaluation et la documentation du processus de mise en œuvre
9. Plaider auprès des bailleurs de fonds et autres sources de financement pour un soutien financier au-delà de la phase pilote
10. Se préparer à plaider pour des changements nécessaires dans les politiques, règlements et autres composantes des systèmes de santé
11. Planifier la façon de promouvoir l'apprentissage et la diffusion de l'information
12. Se préparer à la prudence quant au lancement du passage à grande échelle avant l'obtention des preuves requises

Supplementary File 5: Ethical and funding approval (English translation)**ETHICS APPROVAL**

Research project involving human beings or the consultation of personal information

This research project is reviewed in accordance with the ethical procedures management of research with human beings of Université Laval **by the sectorial committee of research ethics in health science**

Project title	Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare
Researcher's name	Marie-Pierre Gagnon
Approval number	2018-067 / 01-06-2018
Decision date	June 1, 2018
Approval expiration date	July 1, 2019

After reviewing the information and documents it has been provided, the committee notes that the project respects ethical principles of research with human beings. It takes note of the written confirmation of the researcher that she is aware of the follow-up actions¹ associated with ethical approval of this project and that she has agreed to apply them. Therefore, the committee approves this project for one year.

June 6, 2018

Mahmoud Rouabhia, Chair of the
Research Ethics Committee in
Health Sciences

¹ Follow-up action reminder on the next page.

Follow-up actions associated with ethics approval

For the project entitled **Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare** (file number: 2018-067)



1. Notify the Committee in writing without undue delay (independent of its statutory meeting agenda) in the following situations:
 - Any changes to the project, as approved this day, that would include changes to the choice of participants, to recruitment, to the obtention of consent, to the collection of data, and/or to the incurred risks or disadvantages before the application of any such changes (the template of the letter requesting an amendment is available on the CÉRUL website).
 - Any changes to the instrument used for recruitment (ads, posters, or other instruments), to the confirmation of consent (consent form, information sheet, or other forms of confirmation), or to the collection of data (survey, interview grid, or other data collection mechanisms) by providing the latest version of the document under consideration, where changes will be highlighted, before its use.
 - Any unexpected and serious event (e.g. psychological distress of a participant, threat against a person, unexpected or side effects of a product, a drug or a test) that may occur in the course of the current project and would involve a participant, by completing the VRR-EI form available on the CÉRUL website.
 - Any early termination of this research for any reason, be it funded or not, including reasons due to suspension or cancellation on the part of the granting agency.
2. Until the project is finished, and not only for recruitment, submit an annual renewal request for approval by providing a report on research progress, the number of recruited participants, and the difficulties encountered along the way, by using the VRR-107 form. The renewal request must be sent to the committee at least 30 days before the end date of the approval, independent of the statutory meeting agenda.

I, the undersigned, Marie-Pierre Gagnon, declare that I **have read and understood the above follow-up actions associated with ethics approval** and agree to apply them during the entire research project for which I am the principal researcher.

Signature of the principal researcher: _____

Date: 2018-06-04

Supplementary File 6: Ethical approval (original French version)

	
Vice-rectorat à la recherche et à la création Comité d'éthique de la recherche	
<h2>APPROBATION DE L'ÉTHIQUE</h2>	
Projet de recherche impliquant des êtres humains ou la consultation de renseignements personnels	
Ce projet de recherche a été examiné en conformité avec les <i>Modalités de gestion de l'éthique de la recherche sur des êtres humains</i> de l'Université Laval, par le Comité sectoriel d'éthique de la recherche en sciences de la santé	
Projet intitulé :	Personnaliser CONCERTO : L'expérience patient optimisée pour des soins intégrés, coordonnés et efficaces
Nom du chercheur :	Madame Marie-Pierre Gagnon
Numéro d'approbation :	2018-067 / 01-06-2018
Date de décision :	1 ^{er} juin 2018
Date d'expiration de l'approbation :	1 ^{er} juillet 2019
<p>Après examen des informations et des documents qui lui ont été transmis, le Comité a constaté que ce projet respecte les principes d'éthique de la recherche avec des êtres humains. Il prend acte de la confirmation écrite de la chercheuse à l'effet qu'elle a pris connaissance des mesures de suivi¹ associées à l'émission de l'approbation éthique de son projet et qu'elle accepte de les appliquer. Par conséquent, le Comité approuve ce projet pour un an.</p>	
 <hr/> Mahmoud Rouabhia , président Comité d'éthique de la recherche en sciences de la santé	6 juin 2018 <hr/> Date
¹ Rappel des mesures de suivi au verso	
Maison Michael-John-Brophy 2241, chemin Sainte-Foy Québec (Québec) G1V 0A6 CANADA	418 656-2131, poste 4506 Télécopieur : 418 656-2840 cer@vrr.ulaval.ca www.cer.ulaval.ca



Vice-rectorat à la recherche et à la création
Comité d'éthique de la recherche

Mesures de suivi associées à l'approbation éthique

Pour le projet intitulé : **Personnaliser CONCERTO : L'expérience patient optimisée pour des soins intégrés, coordonnés et efficaces** (numéro de dossier : 2018-067)

1. Informer le Comité par écrit et dans les meilleurs délais (indépendamment du calendrier de ses réunions statutaires) des situations suivantes si elles se présentent :
 - de **toute modification au projet**, comme il a été approuvé en ce jour, qui comporterait des changements dans le choix des participants, dans le recrutement, dans la manière d'obtenir leur consentement, de réaliser la collecte des données ou encore, dans les risques ou inconvénients encourus par la participation, et ce, préalablement à l'application de ce changement (modèle de lettre de demande d'amendement disponible sur le site Internet des CÉRUL) ;
 - de **toute modification** qui serait apportée à un **instrument utilisé pour le recrutement** (annonces, affiches, etc.), pour confirmer le **consentement** (formulaire de consentement, feuillet d'information, etc.) ou pour effectuer la **collecte** des données (questionnaire, grille d'entrevue, etc.) en fournissant la nouvelle version du document concerné, où les modifications auront été mises en évidence, préalablement à son utilisation ;
 - de **tout événement imprévu et sérieux** (ex. : détresse psychologique d'un participant, menace proférée à l'égard d'une personne, effets secondaires ou imprévus ou indésirables d'un produit, d'un médicament ou d'un test, etc.) qui surviendrait dans le déroulement d'une activité du présent projet et qui impliquerait un participant, en complétant le formulaire VRR-EI disponible sur le site Internet des CÉRUL ;
 - de **l'interruption prématurée de ce projet de recherche** pour une raison quelconque qu'il soit financé ou non, y compris en raison de la suspension ou de l'annulation de l'approbation d'un organisme subventionnaire.
2. Tant que le projet ne sera pas terminé, et non seulement le recrutement, présenter annuellement une **demande de renouvellement** de l'approbation, en fournissant un rapport sur le déroulement de la recherche, le nombre de participants recrutés et, le cas échéant, sur les difficultés rencontrées en cours de réalisation, à l'aide du formulaire VRR-107. La demande de renouvellement doit être transmise au Comité dans un délai de 30 jours avant la date de fin de l'approbation, indépendamment du calendrier des réunions statutaires.

Maison Michael-John-Brophy
2241, chemin Sainte-Foy
Québec (Québec) G1V 0A6
CANADA

418 656-2131, poste 4506
Télécopieur : 418 656-2840
cer@vrr.ulaval.ca
www.cerul.ulaval.ca

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare
2
3
4

5 **Supplementary File 7: Consent form for validation cycles**

6 This research entitled "Optimizing patient usability experience with an eHealth platform for embedded, coordinated
7 and efficient healthcare" is conducted by Marie-Pierre Gagnon, from faculty of nursing at Université Laval.
8

9 Before you agree to take part in this research project, please take the time to read and understand the following
10 information. This document will explain you the aim of this research project, his process, advantages, risks and
11 disadvantages. We invite you to ask all questions you may deem necessary to the research staff. You can find
12 their contact details at the end of the form.
13
14

15 **Type of study**

16 This research project aims to develop, implement and evaluate a user-centered, multifunctional and personalized
17 eHealth platform (CONCERTO+) to promote a more active patient role in chronic disease management and
18 decision-making, satisfaction towards healthcare services and quality of life. Specific objectives are to:
19

20 1) develop a module of a multifunctional and personalized eHealth platform integrated to the CHP (Concerto Health
21 Program) for patients and caregivers allowing them to engage in the follow-up and management of their chronic
22 diseases;
23

24 2) test the integration of CONCERTO+ in monitoring care pathways of three frequent co-existing chronic diseases
25 (diabetes, hypertension, dyslipidemia) and assess the usefulness and acceptability of the solution for patients with
26 chronic diseases and their caregivers;
27

28 3) assess the scalability of the CONCERTO+ solution.
29
30

31 **The course of the participation:**

32 Validation of the prototype of the application CONCERTO+

33 Your participation in this research will consist in validating the prototype of the application CONCERTO+. In
34 practical terms, you should go to the usability laboratory of Université Laval lead by Dr Holly Witteman. The
35 validation of the application will be done either on a smartphone or a digital tablet. The aim is to collect your input
36 in visual presentation, content, usability of the application, the pros and cons and any consideration of the
37 application developed. Iterative testing via three validation sessions will be organized. If you agree to participate
38 to the validation cycles, your participation may have incur parking and travel expenses. In addition, the participation
39 in each validation cycle requires approximately one and a half hour of your time.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

2 3 4 **Potential benefits and risks or disadvantages related to your participation**

5 There are no direct benefits for the participants. However, this research enables improve the adaptation and value
6 of the CHP in order to provide a multifunctional and personalized eHealth platform, to promote a more active
7 patient and informal care givers role in chronic disease management.
8
9

10 **Compensation**

11 If you participate in validation cycles, we can provide you a lump sum amount of 18 \$ for the time you have
12 allocated for this activity. This sum will be returned in each validation session.
13

14 **Voluntary participation and right to withdraw**

15 You are free to participate to this research project. You may voluntarily withdraw at any time without any
16 justification and with no adverse consequences or without prejudice. However If you decide so, It is important to
17 inform the research team whose contact details are included at the end of the document. All your personal
18 information will be destroyed.
19
20

21 **Confidentiality and data management**

22 The following measures will be applied to ensure your private information stays private:

- 23 •Your name will not be mentioned in any report;
- 24 •The various documents will be codified and only the investigator and his team will have access to the list of names
25 and codes;
- 26 • Your individual results will never be shared;
- 27 • In the interest of scientific rigor, the electronic data will be kept in a folder with a password on the web server of
28 the Canada Research Chair on Technology and Practices in Health at Université Laval. They will be destroyed
29 only five years after the end of the research, in December 2024;
- 30 • This research will be published in scientific reviews and no one can able to identify you;
- 31 • A short summary of the research results will be sent to you if requested by indicating the address where you
32 would like to receive the document, just after the blank space provided for your signature.
33
34

35 **Acknowledgment**

36 Your collaboration is useful to achieve this study, thank you for your participation.
37
38

39 **Additional information**

40 If you have any question on the research, the involvement of your participation or if you want to withdraw from this
41 research, please contact: Mame Awa Ndiaye, research coordinator, Amélie Lampron, research coordinator or
42 Marie-Pierre Gagnon, principal investigator at the following coordinates:

- 43 • Mame Awa Ndiaye: mame-awa.ndiaye.ciusssc@ssss.gouv.qc.ca
- 44 • Amélie Lampron: amelie.lampron2.ciusssc@ssss.gouv.qc.ca
- 45 • Marie-Pierre Gagnon: marie-pierre.gagnon@fsi.ulaval.ca
46

47 **Complaints and criticism**

48 Any complaint and criticism related to this research project will be addressed to the Ombudsman office at
49 Université Laval:

50 Pavillon Alphonse-Desjardins, bureau 3320
51 2325, rue de l'Université
52 Université Laval
53 Québec (Québec) G1V 0A6
54 Information - Secretariat : (418) 656-3081
55
56

57
58 Project approved by the sectorial committee of research ethics in health science of Université Laval (**Approval number 2018-067**),
59 June 1st 2018. MPG

Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

Toll-free line: 1-866-323-2271

Email: info@ombudsman.ulaval.ca

Signatures

I, the undersigned _____ freely consent to participate to the research entitled: «Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare». I have read and understood the aim, type, advantages, risks and disadvantages of the research project. I'm satisfied with the explanations, further details and responses received from the investigator, where appropriate, about my participation to this project.

Participant signature

Date

A short summary of the search results will be sent to you if requested by indicating the address where you would like to receive the document. **The results will not be available before December 20th. If your address changes by that date, you are invited to inform the research team, the new address you wish to receive the document.**

I wish receive a short summary

No, I would prefer not to receive summary

I would like to receive the summary at the following email address or mailing address:

I explained the aim, type of the study, advantages, risks and disadvantages of the research project I have answered to the best of my knowledge the questions asked and have verified the understanding of the participant.

Investigator or research coordinator signature

Date

Copy of the participant.

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

2
3
4 **List of the team members/ Names of project**
5 **partners**

Role in the project

6 Marie-Pierre Gagnon

Specialist of patient engagement and eHealth
technology assessment

7
8
9
10
11 Christian Chabot

Patient partner, co-designer of the project

12
13 Guylaine Chabot, Alain Larouche

Technological partners

14
15 France Légaré, Anik Giguère, Annie LeBlanc

Experts in shared decision making

16
17 Samira Rahimi Abbasgholizadeh

Expert in decision aids tools

18
19 Jean-Paul Fortin, Aude Motulsky, Claude Sicotte

Experts in evaluation of health information
systems

20
21
22 Holly Witteman

Expert in adaptation of user-centered technologies

23
24 Ronald Buyl

Expert in medical informatics and biostatistics

25
26 Carole Délétroz

Expert in health literacy

27
28 Erik Kavanagh, Frédéric Lépinay, Jacynthe
29 Roberge

Specialists in application development and design

30
31
32 Amélie Lampron, Mame Awa Ndiaye

Research coordinators

Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

Supplementary File 8: Consent form (patients and informal caregivers) 2a

This research entitled "Optimizing patient usability experience with an eHealth platform for embedded, coordinated and efficient healthcare" is conducted by Marie-Pierre Gagnon, from faculty of nursing at Université Laval.

Before you agree to take part in this research project, please take the time to read and understand the following information. This document will explain you the aim of this research project, his process, advantages, risks and disadvantages. We invite you to ask all questions you may deem necessary to the research staff. You can find their contact details at the end of the form.

Type of study

This research project aims to develop, implement and evaluate a user-centered, multifunctional and personalized eHealth platform (CONCERTO+) to promote a more active patient role in chronic disease management and decision-making, satisfaction towards healthcare services and quality of life. Specific objectives are to:

- 1) develop a module of a multifunctional and personalized eHealth platform integrated to the CHP (Concerto Health Program) for patients and caregivers allowing them to engage in the follow-up and management of their chronic diseases;
- 2) test the integration of CONCERTO+ in monitoring care pathways of three frequent co-existing chronic diseases (diabetes, hypertension, dyslipidemia) and assess the usefulness and acceptability of the solution for patients with chronic diseases and their caregivers;
- 3) assess the scalability of the CONCERTO+ solution.

The course of the participation:

1) Validation of the prototype of the application CONCERTO+

Your participation in this research will consist in using the application CONCERTO+ (intervention group) or to continue your usual health follow-up (control group). For the participants of the intervention group, the use of the application will be explained to you by the members of the research team. You will complete a short questionnaire at the beginning and at the end of a six months period use, which will focus on the following points:

- Health management
- Feelings in competency and self confidence in health management
- Impacts of CONCERTO+ use
- The use of CONCERTO+

2) Focus group

Your participation in this research consists in participating in a focus group composed of 8 -12 people. The discussion will last approximately two hours and will focus on conditions and factors related to the wide-scale dissemination of the solution CONCERTO+.

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

2 3 4 **Potential benefits and risks or disadvantages related to your participation**

5 There are no direct benefits for the participants. However, participating in this research enables improve the
6 adaptation and value of the CHP in order to provide a multifunctional and personalized eHealth platform, to
7 promote a more active patient and informal care givers role in chronic disease management.
8
9

10 **Compensation**

11 If you accept to participate, a lump sum of 50 \$ will be offered to you for the time you have allocated for this
12 activity. This sum will be returned to you during the focus group discussion.
13
14

15 **Voluntary participation and right to withdraw**

16 You are free to participate to this research project. You may voluntarily withdraw at any time without any
17 justification and with no adverse consequences or without prejudice. However If you decide so, It is important to
18 inform the research team whose contact details are included at the end of the document. All your personal
19 information will be destroyed.
20
21

22 **Confidentiality and data management**

23 The following measures will be applied to ensure your private information stays private:

- 24 •Your name will not be mentioned in any report;
- 25 •The various documents will be codified and only the investigator and his team will have access to the list of
26 names and codes;
- 27 • Your individual results will never be shared;
- 28 • In the interest of scientific rigor, the electronic data will be kept in a folder with a password on the web server of
29 the Canada Research Chair on Technology and Practices in Health at Université Laval. They will be destroyed
30 only five years after the end of the research, in December 2024;
- 31 • This research will be publicated in scientific reviews and no one can able to identify you;
- 32 • A short summary of the research results will be sent to you if requested by indicating the address where you
33 would like to receive the document, just after the blank space provided for your signature.
34
35

36 **Acknowledgment**

37 Your collaboration is useful to achieve this study, thank you for your participation.
38
39

40 **Additional information**

41 If you have any question on the research, the involvement of your participation or if you want to withdraw from this
42 research, please contact: Mame Awa Ndiaye, research coordinator, Amélie Lampron, research coordinator or
43 Marie-Pierre Gagnon, principal investigator at the following coordinates:

- 44 • Mame Awa Ndiaye: mame-awa.ndiaye.ciussscn@ssss.gouv.qc.ca
- 45 • Amélie Lampron: amelie.lampron2.ciussscn@ssss.gouv.qc.ca
- 46 • Marie-Pierre Gagnon: marie-pierre.gagnon@fsi.ulaval.ca
47

48 **Complaints and criticism**

49 Any complaint and criticism related to this research project will be addressed to the Ombudsman office at
50 Université Laval:

51 Pavillon Alphonse-Desjardins, bureau 3320
52 2325, rue de l'Université
53 Université Laval
54 Québec (Québec) G1V 0A6
55 Information - Secretariat : (418) 656-3081
56
57

58 Project approved by the sectorial committee of research ethics in health science of Université Laval (**Approval number 2018-067**),
59 June 1st 2018. MPG

Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

Toll-free line: 1-866-323-2271

Email: info@ombudsman.ulaval.ca

Signatures

I, the undersigned _____ freely consent to participate to the research entitled: «Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare». I have read and understood the aim, type, advantages, risks and disadvantages of the research project. I'm satisfied with the explanations, further details and responses received from the investigator, where appropriate, about my participation to this project.

Participant signature

Date

Do you wish to participate in the first step of this research involving the use of application CONCERTO+ and the completion of two questionnaires on the active involvement?

Yes, i accept to participate No, i would prefer not to participate

Do you wish to participate in the second step of the project involving the participation in a focus group on factors and conditions related to the wide-scale dissemination of the solution CONCERTO+?

Yes, i accept to participate No, i would prefer not to participate

A short summary of the search results will be sent to you if requested by indicating the address where you would like to receive the document. **The results will not be available before December 20th. If your address changes by that date, you are invited to inform the research team, the new address you wish to receive the document.**

I wish receive a short summary No, I would prefer not to receive summary

I would like to receive the summary at the following email address or mailing address:

I explained the aim, type of the study, advantages, risks and disadvantages of the research project I have answered to the best of my knowledge the questions asked and have verified the understanding of the participant.

Investigator or research coordinator signature

Date

Copy of the participant.

Project approved by the sectorial committee of research ethics in health science of Université Laval (**Approval number 2018-067**), June 1st 2018. MPG

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare
2
3

4 **Supplementary File 9: Consent form (interviews)**

5
6 This research entitled "Optimizing patient usability experience with an eHealth platform for embedded, coordinated
7 and efficient healthcare" is conducted by Marie-Pierre Gagnon, from faculty of nursing at Université Laval.
8
9

10 Before you agree to take part in this research project, please take the time to read and understand the following
11 information. This document will explain you the aim of this research project, his process, advantages, risks and
12 disadvantages. We invite you to ask all questions you may deem necessary to the research staff. You can find
13 their contact details at the end of the form.
14
15

16 **Type of study**

17 This research project aims to develop, implement and evaluate a user-centered, multifunctional and personalized
18 eHealth platform (CONCERTO+) to promote a more active patient role in chronic disease management and
19 decision-making, satisfaction towards healthcare services and quality of life. Specific objectives are to:
20

21 1) develop a module of a multifunctional and personalized eHealth platform integrated to the CHP (Concerto Health
22 Program) for patients and caregivers allowing them to engage in the follow-up and management of their chronic
23 diseases;
24

25 2) test the integration of CONCERTO+ in monitoring care pathways of three frequent co-existing chronic diseases
26 (diabetes, hypertension, dyslipidemia) and assess the usefulness and acceptability of the solution for patients with
27 chronic diseases and their caregivers;
28

29 3) assess the scalability of the CONCERTO+ solution.
30

31 **The course of the participation:**

32 Your participation to this research consists in participating in one-on-one semi-structured interview with a
33 member of the team. This interview will last approximately 30 minutes and will focus on the following points:
34

- 35 • Factors facilitating the use of CONCERTO+
- 36 • Factors limiting the use of CONCERTO+
- 37 • Support to the use of CONCERTO+ by health professionals
- 38 • Expansion of CONCERTO+
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57

Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

Potential benefits and risks or disadvantages related to your participation

There are no direct benefits for the participants. However, participating in this research enables improve the adaptation and value of the CHP in order to provide a multifunctional and personalized eHealth platform, to promote a more active patient and informal care givers role in chronic disease management.

Compensation

If you accept to participate, a lump sum of 50 \$ will be offered to you for the time you have allocated for this activity. This sum will be returned to you during the focus group discussion.

Voluntary participation and right to withdraw

You are free to participate to this research project. You may voluntarily withdraw at any time without any justification and with no adverse consequences or without prejudice. However If you decide so, It is important to inform the research team whose contact details are included at the end of the document. All your personal information will be destroyed.

Confidentiality and data management

The following measures will be applied to ensure your private information stays private:

- Your name will not be mentioned in any report;
- The various documents will be codified and only the investigator and his team will have access to the list of names and codes;
- Your individual results will never be shared;
- In the interest of scientific rigor, the electronic data will be kept in a folder with a password on the web server of the Canada Research Chair on Technology and Practices in Health at Université Laval. They will be destroyed only five years after the end of the research, in December 2024;
- This research will be publicated in scientific reviews and no one can able to identify you;
- A short summary of the research results will be sent to you if requested by indicating the address where you would like to receive the document, just after the blank space provided for your signature.

Acknowledgment

Your collaboration is useful to achieve this study, thank you for your participation.

Additional information

If you have any question on the research, the involvement of your participation or if you want to withdraw from this research, please contact: Mame Awa Ndiaye, research coordinator, Amélie Lampron, research coordinator or Marie-Pierre Gagnon, principal investigator at the following coordinates:

- Mame Awa Ndiaye: mame-awa.ndiaye.ciusscn@ssss.gouv.qc.ca
- Amélie Lampron: amelie.lampron2.ciusscn@ssss.gouv.qc.ca
- Marie-Pierre Gagnon: marie-pierre.gagnon@fsi.ulaval.ca

Complaints and criticism

Any complaint and criticism related to this research project will be addressed to the Ombudsman office at Université Laval:

Pavillon Alphonse-Desjardins, bureau 3320
2325, rue de l'Université
Université Laval
Québec (Québec) G1V 0A6
Information - Secretariat : (418) 656-3081

Project approved by the sectorial committee of research ethics in health science of Université Laval (Approval number 2018-067), June 1st 2018. MPG

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

2
3
4 Toll-free line: 1-866-323-2271

5 Email: info@ombudsman.ulaval.ca

8 Signatures

9 I, the undersigned _____ freely consent to participate to the research entitled:
10 «Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient
11 healthcare». I have read and understood the aim, type, advantages, risks and disadvantages of the research
12 project. I'm satisfied with the explanations, further details and responses received from the investigator, where
13 appropriate, about my participation to this project.
14

15
16 _____
17 Participant signature

_____ Date

18
19 A short summary of the search results will be sent to you if requested by indicating the address where you would
20 like to receive the document. **The results will not be available before December 20th. If your address changes
21 by that date, you are invited to inform the research team, the new address you wish to receive the
22 document.**

23
24 I wish receive a short summary

No, I would prefer not to receive summary

25
26 I would like to receive the summary at the following email address or mailing address:
27

28
29 _____
30 _____
31

32
33 I explained the aim, type of the study, advantages, risks and disadvantages of the research project I have
34 answered to the best of my knowledge the questions asked and have verified the understanding of the
35 participant.
36

37
38 _____
39 Investigator or research coordinator signature

_____ Date

40 Copy of the participant.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

Supplementary File 10: Funding



AUTHORIZATION FOR FUNDING
 CIHR (Canadian Institutes of Health Research) has approved funding as detailed below. Subject to the approval of funding by Parliament, these funds will be made available to the business officer at the indicated institution for disbursement.

AUTORISATION DE FINANCEMENT
 IRSC (Instituts de recherche en santé du Canada) vous accorde les fonds tel qu'indiqué ci-dessous. Suivant l'affectation des crédits par le Parlement du Canada, les fonds seront mis à la disposition du trésorier de l'établissement indiqué qui s'occupera des versements.

201706PCG-385330-PCG-CFBA-111141

20/12/2017

Institution Paid/Établissement chargé d'administrer les fonds:
 Université Laval

Recipient(s)/Bénéficiaire(s):
 Gagnon, Marie-Pierre
 CHU de Québec

Program/Programme:
 Subvention catalyseur: Subventions Catalyseur sur la santé personnalisée
 Nouvelle subvention

In Partnership with/En partenariat avec : IRSC - Grandes initiatives #2; IRSC - Institut du Cancer; IRSC - Inst santé femmes et hommes; IRSC - Inst services politiq de santé; IRSC - Institut de génétique; IRSC - Institut du vieillissement

Primary Institute/Institut principal: Services et politiques de la santé

Project Title/Titre du projet:

Personnaliser CONCERTO; L'expérience patient optimisée pour des soins intégrés, coordonnés et efficaces

Co-Investigator(s) & Associates/Supervisor(s)/Host/Co-chercheur(s)/Directeur(s) de recherche/Hôte:

Dr. Samira Abbasgholizadeh Rahimi, Prof. Ronald Buyl, Mr. Christian Chabot, Docteur Jean-Paul Fortin, et coll.

PAYMENT DETAILS/DÉTAILS DES VERSEMENTS		Funding Reference Number/ No. de Référence du financement:	PCG — 155469
Period Période	Type	Amount by Type Montant par type	Total by Fiscal Year Total par exercice
01/09/2017 à 31/03/2018	Fonctionnement	\$58,080	\$58,080 2017-18
01/04/2018 à 31/03/2019	Fonctionnement	\$99,881	\$99,881 2018-19
01/04/2019 à 31/08/2019	Fonctionnement	\$41,568	\$41,568 2019-20

Progress Report Required: Rapport des progrès réalisés requis: **Ne s'applique pas** **Application to Renew Funding Required:** Demande de renouvellement des fonds requis: **Non Renouvelable**

NOTES:
 Les IRSC exigent que leur contribution à votre recherche soit reconnue dans toutes les présentations écrites et orales de vos résultats de recherche, qu'il s'agisse d'articles scientifiques, de communications, de conférences de presse, de conférences publiques ou d'entrevues avec les médias. Votre numéro de référence du financement (NRF), qui apparaît dans la section « Détails des paiements » ci-dessus, doit être précisé lorsqu'il est question d'articles scientifiques pour lesquels le soutien des IRSC est reconnu. Veuillez consulter les lignes directrices des IRSC ci-jointes en matière de communications publiques pour plus de détails sur les communications publiques et les exigences relatives à la reconnaissance du soutien.
 Vous avez reçu ces fonds grâce à vos collègues qui ont donné de leur temps pour aider les IRSC à étudier votre demande. En retour, nous vous demandons de bien vouloir participer aux activités d'évaluation par les pairs des IRSC si on vous invite à le faire.
 En retirant les fonds offerts dans le cadre de cette subvention/bourse, vous acceptez par le fait même les modalités énoncées dans le document « Conditions de financement » ci-joint. Toute dérogation pourrait entraîner la prise de mesures correctives par les IRSC comme précisé à cet égard.
 Si vous recevez ou devenez admissible à recevoir du financement d'une autre source pour l'une ou l'autre des parties du projet visé, vous devez en informer les IRSC immédiatement en suivant les instructions données dans le formulaire « Déclaration de chevauchement de financement » que vous trouverez à l'adresse <http://www.cihr-irsc.gc.ca/f/797.html>, faute de quoi les IRSC pourraient annuler tout le financement lié à cette subvention.
 La présente est une subvention d'un terme de 2 ans qui sera payée dans les années financières 2017-18 et 2019-20 avec une date d'entrée en vigueur du 01/09/2017 couvrant la période jusqu'au 31/08/2019.
 Les IRSC vous demanderont de soumettre un rapport final électronique pour cette subvention par le Système de rapports de recherche sur RechercheNet. Des instructions vous seront fournies par courrier électronique provenant de RechercheNet dès que l'activité deviendra disponible.

Nathalie Gendron
 Nathalie Gendron, Ph.D.
 Gestionnaire, Exécution des concours
 Conception et exécution des programmes
 Portefeuille de la recherche, de l'application des connaissances et de l'éthique

- cc — Supervisor/Directeur
- Dean/Doyen
- Host/Hôte
- Administration
- Accountant/Comptable
- CIHR Finance/Service des Finances d'IRSC
- Other/Autre





STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

Pages
6
9

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

13
13
13
13-15

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	15
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	17
Methods: Assignment of interventions (for controlled trials)			
Allocation:			19
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	19
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	
Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	20
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	21
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	40
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	21-22
	31b	Authorship eligibility guidelines and any intended use of professional writers	
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary Files 6-8
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

Optimizing patient active role with a user-centered eHealth platform (CONCERTO+) in chronic diseases management: A study protocol for a pilot cluster randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028554.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Jan-2019
Complete List of Authors:	Gagnon, Marie-Pierre; Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval; Université Laval, Faculty of nursing Ndiaye, Mame-Awa; Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval Larouche, Alain; Groupe Santé Concerto Chabot, Guylaine; Groupe Santé Concerto Chabot, Christian; International Business Machines Corporation Buyl, Ronald; Vrje Universiteit Brussel, Jette, Belgium Fortin, Jean-Paul; Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval; Université Laval, Department of Family and Emergency Medicine Giguere, Anik; Department of Family and Emergency Medicine, Université Laval; Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval LeBlanc, Annie; Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval Legare, France; Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval; Department of Family and Emergency Medicine, Université Laval Motulsky, Aude; Department of Health Management, Evaluation and Policy, School of Public Health Sicotte, Claude; Department of Health Management, Evaluation and Policy, School of Public Health, Université de Montréal, QC, Canada Witteman, Holly; Department of Family and Emergency Medicine, Université Laval Kavanagh, Eric; École de design, Université Laval Lépinay, Frédéric; École de design, Université Laval Roberge, Jacynthe; École de design, Université Laval Déléroz, Carole; School of Health Sciences (HESAV), HES-SO University of Applied Sciences and Arts Western Switzerland Lausanne Abbasgholzadeh, Samira Rahimi; McGill University, Department of Family Medicine, Montréal, Canada
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Nursing
Keywords:	Chronic disease management, Multimorbidity, eHealth, Health Literacy,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	User-centered design, Patient and caregiver engagement

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Optimizing patient active role with a user-centered eHealth platform (CONCERTO+) in chronic diseases management: A study protocol for a pilot cluster randomized controlled trial

Marie-Pierre Gagnon^{1, 2}, Mame Awa Ndiaye¹, Alain Larouche³, Guylaine Chabot³, Christian Chabot⁴, Ronald Buyl⁵, Jean-Paul Fortin¹, Anik Giguère⁶, Annie LeBlanc⁶, France Légaré^{1, 6}, Aude Motulsky⁷, Claude Sicotte⁷, Holly O. Witteman⁶, Éric Kavanagh⁸, Frédéric Lépinay⁸, Jacynthe Roberge⁸, Carole Délétroz⁹, Samira Rahimi Abbasgholizadeh¹⁰

Author's affiliations

¹Centre de Recherche sur les Soins et les Services de Première Ligne de l'Université Laval, Quebec City, QC, Canada

² Faculty of Nursing, Université Laval, Quebec City, QC, Canada

³ Groupe Santé Concerto, Montréal, QC, Canada

⁴ Patient expert, Quebec City, QC, Canada

⁵ Vrje Universiteit Brussel, Jette, Belgium

1
2
3 ⁶ Department of Family and Emergency Medicine, Université Laval, Quebec City, QC, Canada
4
5

6 ⁷ Department of Health Management, Evaluation and Policy, School of Public Health, Université
7 de Montréal, QC, Canada
8
9

10 ⁸ École de design, Université Laval, Quebec City, QC, Canada
11
12

13 ⁹ School of Health Sciences (HESAV), HES-SO University of Applied Sciences and Arts Western
14 Switzerland Lausanne.
15
16

17 ¹⁰ Department of Family Medicine, McGill University, Montréal, Canada
18
19
20
21
22
23

24 Correspondence to

25
26 Pr Marie-Pierre Gagnon; marie-pierre.gagnon@fsi.ulaval.ca
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction Multimorbidity increases care needs and primary care use among people with chronic diseases. The Concerto Health Program (CHP) has been developed to optimize chronic disease management in primary care services. However, in its current version, the CHP primarily targets clinicians and does not aim to answer directly patients' and their informal caregivers' needs for chronic disease management. Various studies have shown that interventions that increase patient activation level are associated with better health outcomes. Furthermore, educational tools must be adapted to patients and caregivers in terms of health literacy and usability. This project aims to develop, implement and evaluate a user-centered, multifunctional and personalized eHealth platform (CONCERTO+) to promote a more active patient role in chronic disease management and decision-making.

1
2
3 **Methods and analysis** This project uses a collaborative research approach,
4
5
6
7 aiming at the personalization of CHP through 3 phases: 1) the development of
8
9
10
11 one module of an eHealth platform combining scientific evidence and user-
12
13
14 centered design; 2) a feasibility study of CONCERTO+ through a pilot cluster
15
16
17 randomized controlled trial where patients with chronic disease from a primary
18
19
20
21
22
23 healthcare practice will receive CONCERTO+ during 6 months and be compared
24
25
26 to patients from a control practice receiving usual care; and 3) an analysis of
27
28
29
30 CONCERTO+ potential for scaling up. To do so, we will conduct two focus
31
32
33
34 groups with patients and informal caregivers and individual interviews with health
35
36
37 professionals at the two study sites, as well as health care managers, information
38
39
40
41 officers and representatives of the Ministry of Health.
42
43
44
45
46
47
48
49

50 **Ethics and dissemination** This study received ethical approval from Ethics
51
52
53
54
55
56
57
58
59
60
Committee of Université Laval. The findings will be used to inform the

1
2
3 effectiveness of CONCERTO+ to improve management care in chronic disease.
4
5

6
7 We will disseminate findings through presentations in scientific conferences and
8
9
10
11 publication in peer reviewed journals.
12
13

14
15
16
17
18
19
20 **Trial registration:** Clinicaltrials.gov ID: NCT03628963
21
22

23
24 **Keywords:** Chronic disease management, Multimorbidity, eHealth, Patient and
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
caregiver engagement, Health literacy, User-centered design.

Strengths and limitations of this study

- The design of a user-centered technological solution is adapted to

1
2
3
4 chronic disease patients' needs and their literacy level.
5
6
7

- 8
- 9 • The inclusion of informal caregivers in the use of CONCERTO+ is a
10
11 novelty.
12
 - 13 • The pilot test will provide data for feasibility, acceptability and usefulness
14
15 of CONCERTO+.
16
17
 - 18 • Good potential for sustainability given that it will be implemented in the
19
20 real context of primary care practice with the collaboration of clinical
21
22 teams.
23
24
 - 25 • As a limitation, this project seems ambitious for its entire achievement
26
27 in two years.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Background

Chronic diseases are the number one cause of mortality in the world, and account for nearly 70% of deaths [1]. In Canada and around the world, multimorbidity, which means people who have more than two chronic diseases, is increasing [2]. In addition to often making life more difficult for people living with these conditions, the rise in multimorbidity is putting pressure on the Canadian healthcare system and causing over-consumption of care and services [3]. In the Province of Quebec, 45% of people aged 20 and over have more than two chronic diseases [4], and 80% of chronic disease consultations are done in primary health care services [5].

1
2
3
4 Multimorbidity increases care needs as well as the complexity of health care
5
6
7 services required in primary care, especially when it comes to applying
8
9
10
11 recommendations for good clinical practices [5]. The total cost of the six most
12
13
14 common chronic diseases in Quebec (ischemic heart disease, cerebrovascular
15
16
17 disease, chronic obstructive pulmonary disease, cancer, hypertension and
18
19 diabetes) has been estimated at 8, 1 billion Canadian dollars, and this may rise up
20
21
22 to 13 billion in 2030 if no substantial change is made [6].
23
24
25
26
27
28
29

30
31 In Quebec, primary care services have the main responsibility to support people
32
33
34 with chronic diseases and their informal caregivers, jointly with other stakeholders
35
36
37 of the local health network [7, 8]. However, primary care services suffer from many
38
39
40 challenges and organizational constraints, in particular, the difficulty of access –
41
42
43
44
45 with a large proportion of Quebecers without a family doctor – and the wait times
46
47
48 that are among the longest in Canada [9, 10]. Furthermore, the fragmentation of
49
50
51
52
53 health care processes and the gaps in information transfer are recognized sources
54
55
56
57
58
59
60

1
2
3 of inefficiency, that make critical the integration and continuity of care for chronic
4
5
6
7 diseases [7, 11]. To overcome these issues, many approaches linking healthcare
8
9
10
11 providers, patients, caregivers and the organization of health care services are
12
13
14 promoted [12]. The central role of patients in the management of their disease,
15
16
17 which depends on their active involvement, is recognized as a key component in
18
19
20
21
22 chronic disease management [13].
23
24
25

26
27 Active patient involvement requires that patients have the knowledge, skills and
28
29
30 self-confidence to manage their health and healthcare [14]. Various studies have
31
32
33
34 shown that interventions increasing patient activation level are associated with
35
36
37
38 better health outcomes [15-22] and decreased costs [23]. However, active patient
39
40
41 involvement and the quality of the interactions with health providers will partially
42
43
44
45 depend on patient's knowledge of the disease and the needed care, in addition to
46
47
48
49 their interpersonal skills as well as their ability to communicate their expectations,
50
51
52
53 needs and preferences to their healthcare team [24, 25]. It is therefore important
54
55
56
57
58
59
60

1
2
3 to offer patients and caregivers relevant information adapted to their health literacy
4
5
6
7 level. According the following definition, “Health literacy is linked to literacy and
8
9
10 entails people’s knowledge, motivation and competences to access, understand,
11
12
13
14 appraise and apply health information in order to make judgements and take
15
16
17
18 decisions in everyday life concerning health care, disease prevention and health
19
20
21
22 promotion to maintain or improve quality of life during the life course” [26]. For their
23
24
25
26 part, health professionals must also have the communicational and interpersonal
27
28
29
30 skills required to work in a team and share information appropriately with patients
31
32
33
34 in order to support their active involvement [24]. Thus, it becomes important to act
35
36
37
38 in advance by supporting patients’ autonomy and involvement in the care dynamic,
39
40
41
42 and by promoting informational and educational relationships in disease
43
44
45 management [25-27]. Therefore, it is crucial that information and educational tools
46
47
48
49 are adapted to patients and caregivers in terms of literacy level and presentation
50
51
52 [28-30].
53
54
55
56
57
58
59
60

1
2
3 eHealth technologies offer a potential to support chronic disease management.
4
5

6
7 Some studies have shown positive effects on clinical processes (better adherence
8
9
10
11 to care protocol, reduced errors and improved monitoring and callback rates), on
12
13
14
15 quality of care and effectiveness, and on patient outcomes [31-36].
16
17

18
19 Systematic reviews support the role of electronic personal health records and
20
21
22
23 electronic portals allowing patient access to their health records in order to promote
24
25
26
27 their active participation in their care [37-39]. However, to achieve expected
28
29
30
31 outcomes, eHealth technologies should first be adopted and used in an appropriate
32
33
34
35 manner by patients and health professionals [40]. Therefore, end-user involvement
36
37
38
39 in the development of eHealth solutions is an imperative [41]. Moreover, eHealth
40
41
42
43 literacy, which is inspired by the health literacy concept but focuses specifically on
44
45
46
47 optimal eHealth solutions use, should be considered in order to ensure that the
48
49
50
51 solutions are adapted to the capabilities of targeted users [30, 42]. While the
52
53
54
55
56
57
58
59
60 number of eHealth solutions continues to increase, with more than 325,000 mobile

1
2
3 health applications in 2017 [43], the majority of them (53%) are used by less than
4
5
6
7 5,000 people and are often abandoned after a short trial period [44-46]. User
8
9
10 involvement – including patients, informal caregivers and health professionals – is
11
12
13 identified to be among the conditions to ensure that eHealth solutions have a real
14
15
16 impact. Thus, all these stakeholders must be involved throughout the different
17
18
19 stages of technology development, from conception to assessment [47]. Based on
20
21
22 efficient chronic care models, high-potential technologies and patient involvement
23
24
25 as active partner of their care, we suggest to develop an innovative and mobilizing
26
27
28 project in order to improve patient care and experience.
29
30
31
32
33
34
35
36
37

38 Methods and analysis:

39
40
41
42
43 The following methods adhere to the Standard Protocol Items Recommendations
44
45
46
47 for Interventional Trials (SPIRIT) guidelines for the reporting of study protocols.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 This project is a collaborative work involving IT developers from CHP, designers,
5
6
7 clinicians, technological partners and patient representatives. The aim is to
8
9
10 develop, implement and evaluate a module of a multifunctional and personalized
11
12
13 eHealth platform, CONCERTO+, through a pilot study for optimizing patient active
14
15
16 role in medical follow-up, decision-making, satisfaction towards healthcare
17
18
19 services and quality of life. The specific objectives are to: 1) develop a module of a
20
21
22 multifunctional and personalized eHealth platform integrated to the CHP for
23
24
25 patients and caregivers allowing them to engage in the follow-up and management
26
27
28 of their chronic diseases; 2) test the integration of CONCERTO+ in monitoring care
29
30
31 pathways of three frequent co-existing chronic diseases (diabetes, hypertension,
32
33
34 dyslipidemia) and assess the usefulness and acceptability of the solution for
35
36
37 patients with chronic diseases and their caregivers; 3) assess the scalability of the
38
39
40
41
42
43
44
45
46
47
48
49 CONCERTO+ solution.

50 51 52 53 Phase 1: Development of the eHealth solution module 54 55 56 57 58 59 60

1
2
3 We will conduct a rapid literature review on the effects of eHealth interventions for
4
5
6
7 supporting active involvement of patients with chronic diseases in their primary
8
9
10
11 care team. For this purpose, we will follow the rapid review method suggested by
12
13
14 Lawani et al. [48] and consider the latest evidence on eHealth interventions for
15
16
17
18 chronic diseases monitoring and care. We will consider the following “Problem,
19
20
21
22 Intervention, Comparison, Outcomes (PICO)” elements: (P): three targeted chronic
23
24
25
26 diseases (diabetes, high blood pressure, dyslipidemia), alone or combined; (I) all
27
28
29 eHealth interventions implemented in primary care and that directly involve patients
30
31
32
33 (e.g. Electronic Medical Records, patient diary, patient portal, specific
34
35
36
37 computerized monitoring for a chronic disease and technological interventions
38
39
40
41 focused on lifestyle modifications; (C): routine follow-up; (O): Health outcomes
42
43
44
45 specific to the disease (e.g. HbA1c for diabetes), generic health outcomes (e.g.
46
47
48
49 mortality, quality of life), patient outcomes (e.g. involvement, personal efficacy) and
50
51
52
53 practices and process outcomes (e.g. test numbers, emergency visits,
54
55
56
57
58
59
60

1
2
3 hospitalizations). First, we will start to consult existing systematic reviews, in
4
5
6
7 particular that of Irizarry et al. [38], and a review of reviews that we have already
8
9
10
11 completed [49]. We will also document issues relating to needs, expectations and
12
13
14 concerns in terms of eHealth solutions for patients, their informal caregivers, and
15
16
17 health care providers. This information will provide evidence summaries describing
18
19
20 each eHealth solution associated with each targeted health issues, as well as
21
22
23 information on the risks and benefits of these solutions. We will then use the
24
25
26 methods suggested by Giguère et al. [50] to develop Decision Boxes to involve
27
28
29 patients and their informal caregivers in the choice of functionalities and contents
30
31
32 to develop in the CONCERTO+ solution, in line with an integrated care system (**Fig.**
33
34
35
36
37
38
39
40
41 **1**).
42
43
44

45 A first prototype will be developed by the design and technology teams, in close
46
47
48 collaboration with researchers, health professionals and patient representatives
49
50
51 who will identify the functionalities to include in the CONCERTO+ solution. Given
52
53
54
55
56
57
58
59
60

1
2
3 the time limit of the project, we will classify the required functionalities in 3 types:
4
5

6
7 1) essential and priority; 2) important but not priority; 3) required in the future.
8
9

10 For the development of the eHealth platform module, a user-centered approach
11
12

13
14 will be used, based on three cycles with users. Iterative testing sessions will take
15
16

17
18 place at the usability laboratory of UL lead by HW, providing all the equipment
19
20

21
22 needed to conduct usability studies. Students in graphic and interaction design,
23
24

25
26 under the direction of three experts from the School of Design of UL (EK, FLP, JR),
27
28

29
30 will participate in the development of the platform's visual environment. An expert
31
32

33
34 in eHealth literacy (CD) will ensure that contents of the clinical monitoring tools
35
36

37
38 already integrated in the CHP are adapted to a general audience according to
39
40

41
42 recommendations of the Health Literacy Guide [51], in addition of tools that provide
43
44

45
46 understandable information (e.g link to a popular glossary of medical terms:
47
48

49 https://publications.santemontreal.qc.ca/uploads/tx_asssmpublications/litteratie_v
50

51
52 [9.pdf](#)).
53
54
55
56
57
58
59
60

1
2
3
4 The integration of the CONCERTO+ solution with the CHP will be ensured by the
5
6
7 Concerto Health Group team who will work closely with the designers and
8
9
10
11 researchers. Health professionals in primary care services from the sites
12
13
14
15 participating in the pilot project will also be consulted to validate the match between
16
17
18 the CONCERTO + solution and care pathways for professionals offered by the
19
20
21
22 CHP.
23
24
25

26 Patient and Public Involvement

27
28
29
30

31 A patient partner (informal caregiver) is involved as research partner at key stages
32
33
34 of the study. His experience in caring of a patient with diabetes informed us on
35
36
37
38 needs of patients, research focus, methods for collecting data for the study and
39
40
41
42 dissemination strategy through patient and citizen groups associations.
43
44
45

46 Our patient partner is invited at each research team meeting to make sure that the
47
48
49
50 research questions are aligned with patients' needs. He gives his input in refining
51
52
53
54
55
56
57
58
59
60

1
2
3 the focus of the research questions. He made valuable contributions in the design
4
5
6
7 of the study.
8
9

10
11 In the first step of the study, the development of the first prototype, our patient
12
13
14
15 partner helped us to recruit patients by sharing the invitation through his personal
16
17
18
19 contacts and network and gave feedback for the pros and cons of the prototype
20
21
22
23 development. He was also invited to contribute in editing the paper and is
24
25
26
27 considered as a coauthor.
28
29
30

31 To develop our dissemination strategy, we will review the results with the patient
32
33
34
35 partner and integrate his feedback to ensure that we presented the results in the
36
37
38
39 most effective way for the general populations. We will send a summary of the
40
41
42
43 research results to study participants who have provided their mailing address in
44
45
46
47 the consent form and we will also organise events for patients and citizen groups
48
49
50
51 and associations, such as outreach communications and scientific café.
52
53
54
55
56
57
58
59
60

1
2
3 In this study, participants will assess the burden of the intervention by
4
5
6
7 participating in focus groups.
8
9

10 11 Phase 2: Pilot cluster randomized clinical trial 12 13

14
15
16 The Phase 2 of the project will consist in a feasibility study based on a pilot cluster
17
18 randomized clinical trial (c-RCT). Given the nature of the intervention, patients with
19
20 chronic diseases are followed by a small team of primary care clinicians.
21
22
23
24
25
26
27
28
29
30
31
32

33 *Study setting* 34 35 36 37

38 The study will be conducted in two Family Medicine Groups (FMG) from the same
39
40 health region (in the province of Quebec) but covering distinct areas, they have
41
42 been selected as the clusters.
43
44
45
46
47
48
49

50 *Eligibility criteria* 51 52 53 54 55 56 57 58 59 60

1
2
3 Patients with two or more targeted chronic diseases (diabetes, hypertension,
4
5
6
7 dyslipidemia) and who had three or more visits in the last 12 months will be eligible.
8
9

10
11 Adults whose legal incompetence has been established by a court are not eligible.
12
13

14 ***Intervention***

15
16
17
18
19 The intervention is the device CONCERTO+, a user-centered, multifunctional and
20
21
22
23
24 personalized eHealth platform. Both groups, experimental and control, have the
25
26
27 same criteria with respect to participant eligibility. Experimental group from FMG 1
28
29
30
31 will use CONCERTO+ application during 6 months. Control group from FMG 2 will
32
33
34
35 not use the application CONCERTO+ but continue to receive usual care. The
36
37
38
39 objective is to assess the feasibility, acceptability and potential effectiveness of the
40
41
42
43 device CONCERTO+.
44
45
46

47 ***Outcomes***

48
49
50
51 Patient involvement in their care following the use of CONCERTO+ will be our
52
53
54
55 primary outcome of interest. We will use Patient Activation Measure (PAM) [52]
56
57
58
59

1
2
3 which is built on patient knowledge, skills and confidence that are directly targeted
4
5
6
7 by the intervention.
8
9

10
11 The score of the activation level obtained (between 0 and 100) shows the degree
12
13 of ability to manage their health with confidence according to the following scale
14
15 ranges: strongly disagree = 1; disagree = 2; agree = 3; strongly agree = 4. Patients
16
17 with a higher activation level are likely to have better health outcomes. Patients
18
19 answer to a survey of 13 questions with the following scoring for each answer:
20
21
22
23
24
25
26
27
28
29
30

- 31 1. Not believing that activation is important (≤ 47)
- 32
33 2. Lack of knowledge or confidence to take action (47.1 - 55.1)
- 34
35
36
37 3. Beginning to take action (55.2 - 67)
- 38
39
40
41 4. Taking action (≥ 67.1).
- 42
43
44
45
46
47
48

49 The PAM 13 questionnaire has been validated in French. We will ask a license to
50
51 use, which is free for up to 250 patients in an academic research context [53]. The
52
53
54
55
56
57
58
59
60

1
2
3 survey will be completed by participants of the two groups at baseline, and six
4
5
6
7 months later. This period of CONCERTO+ use is enough to achieve the intended
8
9
10
11 outcomes.

12
13
14
15 Secondary outcomes of interest are: 1) Impacts of CONCERTO+ use on process
16
17
18
19 indicators and care outcomes, measured with questions adapted from Glasgow et
20
21
22
23 al. [54] and validated in the previous Concerto Health Program (CHP) assessment.

24
25
26 To measure these outcomes, patients will answer to a questionnaire after six
27
28
29
30 months use of CONCERTO+. This questionnaire comprises 5 scales based on the
31
32
33
34 key components of CONCERTO+ and covering the following dimensions: solving-
35
36
37
38 problems/advices, delivery system design/decision support, goal setting/tailoring,
39
40
41
42 follow-up / coordination, overall care. Items are scored on a 5-point scale with the
43
44
45
46 following values: 1 (Almost never); 2 (Generally not); 3 (Sometimes); 4 (Most of the
47
48
49
50 time); 5 (Almost always). For each scale, higher scores are expected to be
51
52
53 associated with better care outcomes.

1
2
3
4 2) The acceptability of the device CONCERTO+ will be assessed by patients and
5
6
7 informal caregivers, at the end of the intervention with:
8
9

10
11 1. A short survey adapted from the Technology Acceptance Model [55] that
12
13 includes 3 criteria (perceived ease of use, perceived usefulness, behavioral
14
15 intention to use) with the following scoring: Strongly disagree = 1; Disagree = 2;
16
17 Agree = 3; strongly agree = 4. Higher scores indicate a better acceptance of the
18
19 use of CONCERTO+.
20
21
22
23
24
25
26
27
28

29
30 2. The use of CONCERTO+ that will be measured by logs (numbers of tests
31
32 ordered, emergency visits, and hospitalizations). (See **Supplementary File 1,**
33
34
35
36
37
38 2).
39
40
41

42 *Participant timeline*

43
44
45
46

47 **Table 1** shows the distribution of outcomes measures through time. The first survey
48
49
50 will be completed at baseline and six months after the use of CONCERTO+, in
51
52
53
54
55
56
57
58
59
60

1
2
3 order to see the effects of the use of CONCERTO+ during the process of care. The
4
5
6
7 second survey will be completed six months after in order to assess the effects of
8
9
10
11 the use of CONCERTO+, and the third survey will be completed by patients and
12
13
14
15 informal caregivers after the intervention in order to assess its acceptability.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Distribution of outcomes measures through time

	Study period			
	Allocation out	Post allocation	Post allocation	Close
Time point	-T1	T1 (at baseline)	T2 (6 months after the use of Concerto+)	T3: During 3 months following the end of the intervention
	Enrolment - Eligibility screen - informed consent - Allocation			
Intervention group	✓	✓	✓	✓
Usual care group	✓			
Assessments				
Main outcome measure: PAM measure		✓	✓	
Secondary outcome measure: Survey adapted from Glasgow and al.			✓	
Technology Acceptance Model			✓	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Logs measures			✓	
Focus groups				✓
Interviews				✓

For peer review only

Sample size calculation

Based on a similar study [56], a sample of 200 patients is enough to detect a difference of 2 points on the PAM score, with a power of 90% and an alpha of 0.05.

Indeed, the assessment of online education intervention to chronic disease patients, showed a significant difference of 6 points on the PAM score in the experimental group (n = 58), whereas the difference was not significant in the control group (n = 68) [56]. Such a difference may be considered clinically significant because each additional point on the PAM score is associated with a 2% decrease in hospitalizations [53]. Considering an attrition rate of 15%, the sample size should remain relevant to detect a difference of at least 2 points on the PAM score, as differences reported in similar studies range from 2.5 to 6.5 points [14].

Recruitment strategy

1
2
3 For the Phase 1, the development of the eHealth solution module, we will recruit 7
4
5
6
7 to 10 patients and informal caregivers from convenience samples of volunteers
8
9
10
11 joined through patient associations and mailing lists of our institution (Université
12
13
14 Laval-UL). Eligible individuals will meet the following criteria: 1) have one or more
15
16
17
18 targeted chronic diseases (diabetes, hypertension, dyslipidemia); 2) had three or
19
20
21
22 more medical visits in the last 12 months; 3) are 18 years old and over; 4) reside
23
24
25
26 in the greater Quebec area; 5) have an interest in technology; 6) are able to speak
27
28
29
30 and read in French; 7) are available to participate in three validation sessions.
31
32

33
34 For the Phase 2, the pilot cluster randomized clinical trial, a note will be added in
35
36
37 the EMR (electronic medical record) of patients who had been preselected, and at
38
39
40
41 their next visit at the FMG, the receptionist will give them an information sheet about
42
43
44
45 the study to invite them to participate. Interested patients will be invited to call the
46
47
48
49 research assistant using a toll free number or to leave their contact information to
50
51
52
53 the receptionist who will forward them to the research assistant. Then, patients will
54
55
56
57
58
59
60

1
2
3 be contacted by the research assistant to validate their eligibility and confirm their
4
5
6
7 interest. Recruitment will end when 100 patients are recruited from each site. We
8
9
10 will ensure an equal distribution of participants according to their sex, and we will
11
12
13 consider specific aspects in patient recruitment, particularly living alone, the
14
15
16 presence of dependents and their literacy level. The recruitment chart is presented
17
18
19
20
21
22 in Fig. 2
23
24
25

26 *Allocation*

27
28
29
30 Patient will be selected randomly with the help of the participating FMG by
31
32
33 searching the local EMR system. A pre-selection of patients will be done by the
34
35
36
37 four nurses involved in chronic disease care at the participating FMG. For each
38
39
40
41 site, a sample of 200 patients (see sample size calculation) stratified by sex, age
42
43
44
45 group and number of chronic diseases, will be randomly preselected by a
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 FMG in the presence of a research team member.
4
5
6
7

8 *Blinding* 9

10
11
12 Given the nature of the intervention, participating patients and healthcare providers
13
14 cannot be blinded, but the outcome assessor will be blinded to participant
15
16
17
18 assignment.
19
20
21
22
23
24

25 Phase 3: Scaling-up potential of the solution 26 27 28

29 For Phase 3, the analysis of CONCERTO+ potential for scaling-up will be done by
30
31
32 documenting factors and conditions associated with the sustainability and scaling-
33
34 up of the solution. To do so, we will conduct: 1) two focus groups with patients and
35
36
37 informal caregivers who participated in the study (1 with the experimental group
38
39
40 and 1 with the control group, each group gathering between 8 and 12 participants);
41
42
43
44
45 2) semi-structured individual interviews with health professionals as well as with
46
47
48
49
50
51
52 health care managers, information officers, and representatives of the Ministry of
53
54
55
56
57
58
59
60

1
2
3 Health and Social Services will be conducted at the two study sites two FMG of
4
5
6
7 one region in the Province of Quebec). The number of interviews will be determined
8
9
10
11 according to the data saturation principle, but is estimated to be around 15
12
13
14 participants in total. Interviews with patients, informal caregivers and health
15
16
17
18 professionals will include questions about factors facilitating or limiting sustained
19
20
21
22 use of the CONCERTO+ solution by patients and informal caregivers, and the
23
24
25
26 support of this use by health professionals, inspired by a recent study on personal
27
28
29
30 electronic health record [57, 58]. Questions for managers and decision-makers will
31
32
33
34 be based on Expand Net framework [59] that proposes 12 elements helping to
35
36
37
38 appreciate the potential of innovation expansion at different time of its progress
39
40
41
42 (see **Supplementary File 3,4**).

43 44 45 46 Data analysis plan

47
48
49
50
51 The study started in 2017 and will end in 2019. Data will be collected managed and
52
53
54
55 analysed at each step of the project. For the phase 1, we started to collect data in
56
57

1
2
3 October 2018; for the phase 2, we will start in April 2019 and the phase 3 will start
4
5
6
7 in November 2019. We will ensure that surveys are correctly completed in order to
8
9
10
11 avoid many missing data. Quantitative data will be analyzed using standard
12
13
14 statistical tests such as ANOVA. We will compare the scores for repeated
15
16
17 measurements between the two groups, controlling for the initial PAM score. We
18
19 will also make tests according to sex, literacy level and comorbidity because these
20
21
22 variables are associated with the PAM score [60]. Focus groups discussions and
23
24
25 interviews will be recorded with participants' consent, and the content will be
26
27
28 transcribed verbatim. The qualitative analysis will consist in a thematic-pragmatic
29
30
31 content analysis [61] using the NVivo 10 software. We will use an inductive-
32
33
34 deductive analysis, in an iteratively and flexible way, which allows a hybrid
35
36
37 codification from the conceptual dimensions of the model and the emergent themes
38
39
40
41
42 [62]. We will verify the role of the identified dimension in the literature as the initial
43
44
45
46
47
48
49
50
51
52
53 basis for analysis, while remaining open to the advent of other context-specific
54
55
56
57
58
59
60

1
2
3 aspects. Findings from qualitative analyses will be triangulated with quantitative
4
5
6
7 data to see commonalities among participants' characteristics. We will compare
8
9
10 intervention and control groups to judge the potential effectiveness of
11
12
13 CONCERTO+ using process and care outcomes, and these results will inform the
14
15
16 relevance of conducting a definitive trial to assess the effectiveness of
17
18
19 CONCERTO+ for improving health outcomes. Participants will also be asked about
20
21
22
23 the usefulness of the CONCERTO+ solution in supporting their disease self-
24
25
26
27 management.
28
29
30
31
32

33 Monitoring

34
35
36
37
38 A Data Monitoring Committee is not required for this study due to low risk of
39
40
41
42 adverse events. The principal investigator has the authority to suspend or terminate
43
44
45
46 the study at any time if any major problem occurs.
47
48
49

50 Ethics and dissemination

1
2
3
4 This study received ethical approval from the Research Ethics Committee of
5
6
7 Université Laval; approval number: 2018-067 /01-06-2018 with all protocol
8
9
10
11 modifications being mandatory to report (see **Supplementary Files 5, 6**). All
12
13
14 participants will provide their informed consent following a procedure approved by
15
16
17 the ethics board (see **Supplementary Files 7-9**) before enrollment in the study. All
18
19
20 data will be anonymized and will be used only for statistical research and analysis.
21
22
23
24
25
26 They will be securely stored on the server of Canadian Research Chair on
27
28
29 Technologies and Practices in Health, we will never share it with third parties. Only
30
31
32 the principal investigator, the research coordinator and eventually students who
33
34
35 work on the project will have access on the list of participants in the different phases
36
37
38 of the project. Data from EMR will be also anonymized by a medical secretary or a
39
40
41 research assistant who will sign a confidentiality agreement. In addition, all team
42
43
44 members will sign a confidentiality agreement so that any personal information of
45
46
47
48
49 participants will not be shared.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 In keeping with our participative approach and inspired by frameworks of
5
6
7 collaboration between researchers and knowledge users [63, 64], knowledge
8
9
10 translation will be done in an integrated way throughout the project, with an
11
12
13 emphasis on collaboration, shared outcomes, and feedback from stakeholders at
14
15
16 each step of the research. We will also share the outcomes through presentations
17
18
19 in the networks and organizations of the team members, and through the
20
21
22 production of dissemination tools for patient and citizen groups and associations.
23
24
25 Ideally, these presentations will be done in tandem (patient-researcher; patient-
26
27
28 clinician) in an interactive way, by taking the time for discussion and exchanges
29
30
31 with the audience (e.g. lunch and learn, scientific café). The presentations will be
32
33
34 supported with materials (brief reports, narrated slideshows, etc.) allowing a
35
36
37 greater dissemination of the activities and outcomes. Knowledge translation
38
39
40 activities at the end of project will consist of publishing outcomes in open access
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 peer reviewed journals. Presentations at national and international conferences in
4
5
6
7 health informatics, chronic diseases, and patient engagement are also scheduled.
8
9

10 11 12 13 14 15 16 17 Study status

18
19
20
21
22 This is an ongoing study taking place from December 2017 until December 2019.
23
24

25
26 At the time of writing, the prototype of the eHealth technology module was designed
27
28
29 and the first usability test was done.
30
31

32 33 34 Discussion

35
36
37
38
39
40 This project shows a potential of success through the involvement of the
41
42
43 technological partner who has a long collaborative experience with researchers.
44
45

46
47 The eHealth solution is also likely to be acceptable because it will be adapted to
48
49
50
51 patient's needs, based on our user-centered approach and the adaptation of the
52
53
54
55 content to users' literacy level. Previous results associated with the use of the CHP
56
57
58

1
2
3 solution for clinicians show promising preliminary outcomes based on validated
4
5
6
7 measures that are relevant and sensitive to the proposed intervention. The solution
8
9
10
11 has also a good potential for sustainability given that it will be implemented in the
12
13
14 real context of primary care practice, with the collaboration of clinical teams. Finally,
15
16
17 the project team is engaged in disseminating the results and pursuing the
18
19 development and adaptation of the CONCERTO+ solution in order to contribute to
20
21
22
23
24
25
26 improving the health of people in Canada and internationally.
27
28
29

30 31 List of abbreviations 32 33 34 35

36 **CHP:** Concerto Health Program
37
38

39
40 **c-RCT:** cluster randomized clinical trial
41
42
43

44 **EMR:** Electronic Medical Record
45
46
47

48 **FMG:** Family medicine Group
49
50
51

52
53 **IT:** Information Technology
54
55
56
57
58
59
60

1
2
3 **PAM:** Patient activation measure
4
5
6

7 **PICO:** Problem, Intervention, Comparison-Outcomes
8
9
10

11 **SPOR:** Strategy of Patient-Oriented Research
12
13
14

15 **UL:** Université Laval
16
17
18

19 20 21 List of figures 22 23 24

25
26 Figure 1: Embedded healthcare system
27
28

29
30 Figure 2: Recruitment flowchart
31
32
33

34 35 References 36 37 38

39
40 1. World Health Organization. WHO - Global status report on
41
42

43 noncommunicable diseases. 2014.
44
45

46
47 http://apps.who.int/iris/bitstream/handle/10665/148114/9789241564854_eng
48
49

50
51 .pdf.
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2. Roberts KC, Rao DP, Bennett TL, Loukine L, Jayaraman GC. Prevalence and patterns of chronic disease multimorbidity and associated determinants in Canada. *Health Promot Chronic Dis Prev Can.* 2015;**35**:87-94.
3. Health Council of Canada. Helping patients help themselves: are Canadians with chronic conditions getting the Support they need to manage their health? 2010. https://healthcouncilcanada.ca/files/2.17-AR1_HCC_Jan2010.pdf
4. Ruel, G. (2012). Multimorbidité : Ampleur, impacts et défi. In: *4e Rendez-vous des maladies chroniques*. Quebec: Institut national de santé publique du Québec (accessed 28 Apr 2017).

- 1
2
3
4
5
6
7
8
9 5. Fortin M, Contant E, Savard C, Hudon C, Poitras M-E, Almirall J. Canadian
10
11
12 guidelines for clinical practice: an analysis of their quality and relevance to
13
14
15
16 the care of adults with comorbidity. *BMC Fam Pract*. 2011;**12**:74.
17
18
19
20
21
22
23
24
25
26 6. Bounajm F, Dinh T, Thériault L: Améliorer les habitudes de vie: des retombées
27
28
29 importantes pour la santé et l'économie du Québec. 2017.
30
31
32 <https://www.conferenceboard.ca/temp/7230eaa9-bb8f-43ae-8ecb>
33
34 [969e71c8c696/6647_SanteEtEconomieDuQuebec_RPT.pdf](https://www.conferenceboard.ca/temp/7230eaa9-bb8f-43ae-8ecb) (accessed 29
35
36
37
38
39
40
41 May 2018).
42
43
44
45
46
47
48 7. The Commissaire à la Santé et au Bien-Être. Adopting an integrated
49
50
51
52 approach to chronic disease prevention and management:
53
54
55
56
57
58
59
60

1
2
3
4 recommendations, issues and implications, 2010.

5
6
7 <https://www.csbe.gouv.qc.ca/fileadmin/www/2010/MaladiesChroniques/CSB>

8
9
10
11 E_T4_Recommandations2010.pdf

- 12
13
14
15
16
17
18
19
20
21 8. Ministère de la Santé et des Services Sociaux. Cadre de référence pour la
22
23
24 prévention et la gestion des maladies chroniques physiques en première

25
26
27
28 ligne.2012. <http://publications.msss.gouv.qc.ca/msss/fichiers/2012/12-942->

29
30
31
32 [01F.pdf](#)

- 33
34
35
36
37
38
39
40
41
42 9. FMOQ, The Fédération des médecins omnipraticiens du Québec.

43
44
45
46 Communiqué de la FMOQ: La FRMOQ lance une nouvelle campagne

47
48
49 publicitaire pour rappeler l'urgence d'investir en médecine familiale. (2011)

50
51
52
53 Montréal.

- 1
2
3
4
5
6
7
8 10. Bates-Eamer N, JL Ronson. Perceived shortage, relative surplus: the
9
10
11 paradox of Quebec's Family physician workforce - An Intra- and
12
13
14 Inter-Provincial Comparison, U.o.V. Centre for Global Studies, Editor. 2009.
15
16
17
18
19
20
21
22
23
24
25 11. OCDE, The Organization for Economic Co-operation and Development:
26
27
28 Promoting health, preventing disease, the economic case.
29
30
31
32 <https://www.oecd-ilibrary.org/docserver/9780335262274->
33
34
35
36 [en.pdf?expires=1535485524&id=id&accname=guest&checksum=37E5F5C](https://www.oecd-ilibrary.org/docserver/9780335262274-en.pdf?expires=1535485524&id=id&accname=guest&checksum=37E5F5C)
37
38
39 [0D17CCC858CBF41B9E570C708](https://www.oecd-ilibrary.org/docserver/9780335262274-0D17CCC858CBF41B9E570C708). In The European Observatory on Health
40
41
42
43 Systems and Policies Series (2015). Accessed 28 August 2018.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 12. Adams SG, Smith PK, Allan PF, Anzueto A, Pugh JA, Cornell JE. Systematic
5
6
7 Review of the Chronic Care Model in Chronic Obstructive Pulmonary
8
9
10
11 Disease Prevention and Management. Arch Intern Med. 2007; **167**:551-61.
12
13
14
15 doi:10.1001/archinte.167.6.551
16
17
18
19
20
21
22 13. Longtin Y, Sax H, Leape LL, Sheridan SE, Donaldson L, Pittet D. Patient
23
24
25 participation: current knowledge and applicability to patient safety Mayo Clin
26
27 Proc. Elsevier. 2010 January;**85**:53-62.
28
29
30
31
32
33
34
35
36
37
38
39
40 14. Hibbard JH, Greene J. What the evidence shows about patient activation:
41
42
43 better health outcomes and care experiences; fewer data on costs. Health
44
45
46
47 affairs. 2013;**32**:207-214.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 15. Greene J, Hibbard JH. Why does patient activation matter? An examination
5
6
7 of the relationships between patient activation and health-related outcomes.
8
9
10
11 J Gen Intern Med. 2012; 27:520-6.
12
13
14
15
16
17
18
19
20

21 16. Hibbard JH, Mahoney E R, Stock R, Tusler, M. Do increases in patient
22
23
24 activation result in improved self-management behaviors?. Health Services
25
26
27
28 Research.2007;42:1443-63.
29
30
31
32
33
34
35
36
37

38 17. Fowles JB, Terry P., Xi M, Hibbard J, Bloom CT, Harvey L. Measuring self-
39
40
41 management of patients' and employees' health: further validation of the
42
43
44
45 Patient Activation Measure (PAM) based on its relation to employee
46
47
48
49 characteristics. Patient Educ Couns. 2009;77:116-22
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 18. Mosen DM, Schmittiel J, Hibbard J, Sobel D, Remmers C, Bellows J. Is
5
6
7 patient activation associated with outcomes of care for adults with chronic
8
9
10
11 conditions? J Ambul Care Manage. 2007;**30**:21.
12
13
14
15
16
17
18
19
20
21 19. Becker ER, Roblin D W. Translating primary care practice climate into patient
22
23
24 activation: the role of patient trust in physician. Med care. 2008;**46**:795-805.
25
26
27
28
29
30
31
32
33
34
35 20. Hibbard JH, Cunningham PJ. How engaged are consumers in their health
36
37
38 and health care, and why does it matter? Res Briefs. 2008;**8**:1-9.
39
40
41
42
43
44
45
46
47
48 21. Remmers C, Hibbard J, Mosen DM, Wagenfield M, Hoye RE, Jones C. Is
49
50
51
52 patient activation associated with future health outcomes and health-care
53
54
55
56
57
58
59
60

1
2
3 utilization among patients with diabetes? J Ambul Care
4
5

6
7 Manage.2009;**32**:320-7.
8
9

- 10
11
12
13
14
15
16
17 22. Donald M, Ware RS, Ozolins IZ, Begum N, Crowther R, Bain C. The role of
18
19
20
21 patient activation in frequent attendance at primary care: a population-
22
23
24 based study of people with chronic disease. Patient Educ Couns.
25
26
27
28 2011;**83**:217-21.
29
30

- 31
32
33
34
35
36
37
38 23. Greene J, Hibbard JH, Sacks R, Overton V, Parrotta CD. When patient
39
40
41
42 activation levels change, health outcomes and costs change, too. Health
43
44
45
46 affairs. 2015;**34**:431-7.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 24. Holmström I, Röing M. The relation between patient-centeredness and
5
6
7 patient empowerment: a discussion on concepts. Patient Educ Couns.
8
9
10
11 2010; **79**:167-72.
12
13

14
15
16
17
18
19
20 25. Pomey MP, Flora, L, Karazivan P, Dumez V, Lebel P, Vanier MC., et al. Le
21
22
23 "Montreal model" : enjeux du partenariat relationnel entre patients et
24
25
26
27 professionnels de la sante. Sante Publique.2015; **HS**:41-50.
28
29

30
31
32
33
34
35
36
37 26. Kickbusch I, Pelikan J, Apfel F, Tsouros A. Health literacy. World Health
38
39
40
41 Organisation 2013.
42
43
44
45 http://www.euro.who.int/__data/assets/pdf_file/0008/190655/e96854.pdf.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 27. Hart JT. The Autonomous Patient: Ending Paternalism in Medical
5
6
7 Care.JRSM.2002; **95**:623-4.
8
9
10
11
12
13
14
15
16
17 28. Koh H.K, Brach C, Harris LM, Parchman ML. A proposed 'health literate care
18
19
20 model' would constitute a systems approach to improving patients'
21
22
23 engagement in care. Health Affairs.2013;**32**:357-67.
24
25
26
27
28
29
30
31
32
33
34 29. Frosch DL, Elwyn G. Don't blame patients, engage them: transforming
35
36
37 health systems to address health literacy. Journal of health
38
39
40 communication.2014;**19**:10-4.
41
42
43
44
45
46
47
48
49 30. Monkman H, Andre W. eHealth literacy issues, constructs, models, and
50
51
52
53
54 methods for health information technology design and evaluation.
55
56
57
58
59
60

1
2
3 Knowledge Management & ELearning: An International Journal
4
5
6

7 (KM&EL).2015;7: 541-9.
8
9

10
11
12
13
14
15
16
17 31. Chaudhry B, Wang J, Wu S, Maglione M, Mojica W, Roth E, Shekelle PG.
18

19
20
21 Systematic review: impact of health information technology on quality,
22

23
24 efficiency, and costs of medical care. Annals of Internal
25

26
27
28 Medicine.2006;**144**:742-52.
29
30

31
32
33
34
35
36 32. Cummings E, Turner P. Patient self-management and chronic illness:
37

38
39 evaluating outcomes and impacts of information technology. Studies in
40

41
42
43 health technology and informatics.2008;**143**:229-34.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 33. Dorr D, Bonner LM, Cohen, AN, Shoai, RS, Perrin R, Chaney E, Young AS.
4
5
6

7 Informatics systems to promote improved care for chronic illness: a
8
9

10 literature review. JAMIA. 2007;**14**:156-63.
11
12
13
14
15
16
17
18
19
20

21 34. Häyrinen K, Saranto K, Nykänen P. Definition, structure, content, use and
22
23

24 impacts of electronic health records: a review of the research literature. Int J
25
26
27

28 Med Inform. 2008;**77**:291-304.
29
30
31
32
33
34
35
36
37

38 35. Lau F, Kuziemy C, Price M, Gardner JA. Review on systematic reviews of
39
40
41

42 health information system studies. JAMIA. 2010;**17**:637-45.
43
44
45
46
47
48
49
50
51

52 36. Rigby M, Georgiou A, Hyppönen H, Ammenwerth E, de Keizer N, Magrabi F,
53
54

55 Scott P. Patient Portals as a Means of Information and Communication
56
57
58
59
60

1
2
3 Technology Support to Patient-Centric Care Coordination – the Missing
4
5
6

7 Evidence and the Challenges of Evaluation. Yearbook of Medical
8
9

10 Informatics 2015;**10**:148-59.
11
12
13
14
15
16
17

18 37. Eland-de Kok, P van Os-Medendorp H, Vergouwe-Meijer A,
19
20

21
22 Bruijnzeel-Koomen C, Ros W. A systematic review of the effects of e-health
23
24
25

26 on chronically ill patients. J ClinNurs, 2011;**20**:2997-3010.
27
28
29
30
31
32
33
34
35

36 38. Irizarry T, Dabbs AD, Curran CR. Patient portals and patient engagement: a
37
38

39 state of the science review. JMIR. 2015;**17**.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 39. Price M, Bellwood P, Kitson N, Davies I, Weber J, Lau F. Conditions
5
6
7 potentially sensitive to a personal health record (PHR) intervention, a
8
9
10
11 systematic review. BMC Med Inform Decis Mak. 2015;**15**:32.
12
13
14
15
16
17
18
19
20
21 40. Ross J, Stevenson F, Lau R, Murray E. Factors that influence the
22
23
24 implementation of e-health: a systematic review of systematic reviews (an
25
26
27
28 update). Implementation Science. 2016;**11**:146.
29
30
31
32
33
34
35
36
37
38 41. Strisland F, Svagård ., Austad H, Reitan J. Meeting end user needs in
39
40
41
42 international research projects aiming to develop medical device technology
43
44
45
46 prototypes for integrated care: A case study. Int J Integr Care 2016;**16**.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 42. Monkman H, KUSHNIRUIC A. Applying usability methods to identify health
5
6
7 literacy issues: an example using a Personal Health Record. Stud Health
8
9
10
11 Technol Inform. 2013; 183:179-85.
12
13
14
15
16
17
18
19
20
21 43. Research2Guidance. mHealth App Developer Economics: The current status
22
23
24 and trends of the mHealth app market, 2017. [https://www.uzelf.org/wp-](https://www.uzelf.org/wp-content/uploads/2017/12/R2G-mHealth-Developer-Economics-2017-Status-And-Trends.pdf)
25
26
27
28 [content/uploads/2017/12/R2G-mHealth-Developer-Economics-2017-Status-](https://www.uzelf.org/wp-content/uploads/2017/12/R2G-mHealth-Developer-Economics-2017-Status-And-Trends.pdf)
29
30
31 [And-Trends.pdf](https://www.uzelf.org/wp-content/uploads/2017/12/R2G-mHealth-Developer-Economics-2017-Status-And-Trends.pdf).
32
33
34
35
36
37
38
39
40
41
42 44. Greenhalgh T, Hinder S, Stramer K, Bratan T, Russell J. Adoption, non-
43
44
45 adoption, and abandonment of a personal electronic health record: case
46
47
48
49 study of HealthSpace. BMJ. 2010;**341**:c5814.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 45. Garabedian, LF, Ross-Degnan, D, Wharam JF. Mobile phone and
5
6
7 smartphone technologies for diabetes care and self-management. Current
8
9
10
11 diabetes reports. 2015;**15**:109.
12
13
14
15
16
17
18
19 46. Group N. Catalyst Insights Council Monthly Report: How to Hardwire Patient
20
21
22 Engagement into Care Delivery Processes, 2017.
23
24
25
26 [https://join.catalyst.nejm.org/hubfs/Insights%20Council%20Monthly%20-](https://join.catalyst.nejm.org/hubfs/Insights%20Council%20Monthly%20-%20Files/Insights%20Council%20Monthly%20May%202017%20Report_How%20to%20Hardwire%20Patient%20Engagement%20into%20Care%20Delivery%20Processes.pdf)
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 47. Khoja S, Durrani H, Scott RE, Sajwani A, Piryani U. Conceptual framework
46
47
48
49 for development of comprehensive e-health evaluation tool. Telemedicine
50
51
52
53 and e-Health. 2013;**19**:48-53.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9 48. Lawani MA, Valéra B, Fortier-Brochu É, Légaré F, Carmichael PH, Côté L,
10
11
12 Giguere AM. Five shared decision-making tools in 5 months: use of rapid
13
14
15
16 reviews to develop decision boxes for seniors living with dementia and their
17
18
19 caregivers. *Systematic reviews*. 2017;**6**:56.
20
21
22
23
24
25
26
27
28

29
30 49. Zanaboni P, Ngangue P, Mbemba GIC, Schopf TR, Bergmo TS, Gagnon M
31
32
33 P. Methods to Evaluate the Effects of Internet-Based Digital Health
34
35
36
37 Interventions for Citizens: Systematic Review of Reviews. *JMIR*.
38
39
40
41 2018;**20**e10202.
42
43
44
45
46
47
48
49
50

51 50. Giguere AM, Labrecque M, Haynes RB, Grad R, Pluye P, Légaré F, et al.
52
53
54 Evidence summaries (decision boxes) to prepare clinicians for shared
55
56
57
58
59
60

1
2
3 decision-making with patients: a mixed methods implementation study.
4
5

6
7 Implement Sci.2014;**9**:144.
8
9

10
11
12
13
14
15
16
17 51. Lemieux V. Pour qu'on se comprenne: guide de littérature en santé, 2014.
18

19
20
21 https://publications.santemontreal.qc.ca/uploads/tx_ assmpublications/litter
22
23
24 [atie_v9.pdf](#).
25
26

27
28
29
30
31
32 52. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of
33
34
35
36 a short form of the patient activation measure. Health Services
37

38
39
40 Research.2005;**40**:1918-30.
41
42
43
44
45
46
47
48
49

50 53. Health I. Patient Activation Measure, 2014. <http://www.insigniahealth.com/>
51
52
53
54
55
56
57
58
59
60

1
2
3 54. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM.
4
5

6
7 Development and validation of the patient assessment of chronic illness
8

9
10
11 care (PACIC). Medical care. 2005;436-44.
12
13

14
15
16
17
18
19
20
21 55. Davis FD. Perceived usefulness, perceived ease of use, and user
22

23
24 acceptance of information technology. MIS quarterly.1989:319-40.
25
26

27
28
29
30
31
32
33
34 56. Solomon M, Wagner SL, Goes J. Effects of a Web-based intervention for
35

36
37 adults with chronic conditions on patient activation: online randomized
38

39
40
41 controlled trial. JMIR. 2012;14:e32.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 57. Ghandour E, Gagnon M-P, Fortin J-P. Patient adoption of a connected
5
6
7 electronic personal health record to support chronic disease management in
8
9
10
11 primary care in Quebec. Submitted for publication.
12
13
14
15
16
17
18
19
20

21 58. Ghandour E, Gagnon M-P, Fortin J-P. Conditions d'adoption du dossier de
22
23
24 santé électronique personnel par les professionnels de la première ligne au
25
26
27
28 Québec : Perspectives professionnelle et organisationnelle. Revue Santé
29
30
31 Publique. 2017; **29**:837-850.
32
33
34
35
36
37
38
39
40
41

42 59. World Health Organization. Beginning with the end in mind planning pilot
43
44
45 projects and other programmatic research for successful scaling up,
46
47
48
49 2014.[https://www.who.int/reproductivehealth/publications/strategic_approac](https://www.who.int/reproductivehealth/publications/strategic_approach/9789241502320/en/)
50
51
52
53 [h/9789241502320/en/](https://www.who.int/reproductivehealth/publications/strategic_approach/9789241502320/en/)
54
55
56
57
58
59
60

1
2
3
4
5
6
7 60. Hendriks M, Rademakers J. Relationships between patient activation,
8
9
10
11 disease-specific knowledge and health outcomes among people with
12
13
14
15 diabetes; a survey study. BMC health serv res. 2014;**14**:393.
16
17
18
19
20
21
22
23

24 61. Aronson J. A pragmatic view of thematic analysis. Qualitative
25
26
27
28 Report.1994;**2**:1-3
29
30
31
32
33
34
35
36
37

38 62. Miles MB, Huberman AM. Qualitative data analysis: An Expanded
39
40
41
42 Sourcebook. Sage. 2003.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 63. Parry D, Salsberg J, Macaulay AC, et al. A Guide to Researcher and
5
6
7 Knowledge-User Collaboration in Health Research. C.I.o.H.R. (CIHR)
8
9
10
11 Editor. 2009:83.
12
13
14
15
16
17
18
19
20

21 64. Baumbusch JL, Kirkham SR, Khan KB, McDonald H, Semeniuk P, Tan E,
22
23
24 Anderson JM. Pursuing common agendas: a collaborative model for
25
26
27
28 knowledge translation between research and practice in clinical settings.
29
30
31
32 Res Nurs Health. 2008; **31**:130-40.
33
34
35
36
37
38
39
40
41
42

Footnotes

43 **Protocol version:** Version 1 (November 15th 2018)
44
45
46
47
48
49
50

51 **Funding:** This study is funded by the Canadian Institutes of Health Research.
52
53
54
55
56
57
58
59
60

Funding Reference Number: PCG-155469.

1
2
3 **Authors' contributions:** MPG, AL, GC, and CC conceived and designed the study
4
5
6
7 and drafted the manuscript. AG, JPF, FL, HW, ALB, RB, CS, AM, SRA, CD, EK,
8
9
10
11 FLP, JR, MAN participated in designing the study and revised the manuscript. All
12
13
14
15 authors read and approved the final manuscript.
16
17
18

19 **Competing interest:** The authors declare that they have no competing interests.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 1 Embedded Healthcare System

Phase 1



Phase 2



Phase 3




Figure 2 Recruitment flowchart

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary File 1: Mesure d'activation du patient (PAM-13) French translation

1. Activation du patient	
Outil utilisé	
Mesure d'activation du patient (<i>Patient Activation Measure-PAM-13</i>)	
Critères ¹	
<ol style="list-style-type: none"> 1. En fin de compte, je suis la personne qui est responsable de gérer ma condition de santé 2. Prendre un rôle actif dans mes soins de santé et le facteur le plus important pour déterminer ma santé et mon habileté pour fonctionner 3. Je suis confiant que je peux prendre des actions qui m'aideront à prévenir ou minimiser certains symptômes ou problèmes associés avec ma condition de santé 4. Je sais quels sont les effets de tous mes médicaments prescrits 5. Je suis persuadé que je peux savoir quand j'ai besoin de soins médicaux et quand je peux gérer mes problèmes de santé par moi-même 6. Je suis persuadé que je peux exprimer à mon professionnel de la santé mes préoccupations même quand il ou elle ne le demande pas 7. Je suis convaincu que je peux appliquer les traitements médicaux dont j'ai besoin à la maison 8. Je comprends la nature et les causes de ma condition de santé 9. Je connais les différentes options de traitements médicaux qui sont disponibles pour ma condition de santé 10. J'ai été capable de maintenir des changements de style de vie que j'ai adopté pour ma santé 11. Je sais comment prévenir des problèmes ultérieurs en lien avec ma condition de santé 12. Je suis confiant que je peux trouver des solutions quand des nouvelles situations ou problèmes apparaissent en lien avec ma condition de santé 13. Je suis persuadé que je peux maintenant des changements de style de vie comme une diète et de l'exercice même durant des périodes de stress 	
Mesure des résultats	
<p>Notation (pour chaque critère) :</p> <ul style="list-style-type: none"> ▪ Fortement en désaccord (1 point) ▪ En désaccord (2 points) ▪ En accord (3 points) ▪ Fortement en accord (4 points) <p>Niveaux d'activation (selon la conversion des résultats sur un score de 100) :</p> <ol style="list-style-type: none"> 1. Ne croit pas que l'activation est important (≤ 47) 2. Manque de savoir ou de confiance pour agir (47.1-55.1) 3. Commence à agir (55.2-67) 4. Agit (≥ 67.1) 	

¹ Adapté de: Moljord I E O, Lara-Cabrera ML, Perestelo-Pérez L, Rivero-Santana A, Eriksen L, Linaker OM. Psychometric properties of Patient Activation Measure-13 among out-patients waiting for mental health treatment: a validation study in Norway. *Patient education and counseling*. 2015;98(11):1410-1417.

Traduction libre

2. Impacts de l'utilisation de CONCERTO+

Outil utilisé

Questionnaire utilisé lors de l'évaluation de la phase pilote du Programme de santé Concerto¹

Critères²

Résolution de problèmes/conseils :

1. Vous a-t-on demandé quels étaient les effets de votre maladie sur votre vie ?
2. Vous a-t-on aidé à planifier afin de pouvoir prendre soin de votre état de santé même en des moments difficiles ?
3. Vos fournisseurs de soins tenaient-ils compte de vos valeurs et de vos traditions au moment de vous recommander un traitement ?
4. Vous a-t-on aidé à élaborer un plan de traitement que vous pourriez mettre en pratique dans votre vie quotidienne ?

Prestation de soins/aide à la décision :

1. Vous a-t-on posé des questions sur vos habitudes de santé ?
2. Vous a-t-on encouragé à faire partie d'un groupe ou d'une classe, comme une session d'information éducative, pour vous aider à vivre avec votre état de santé chronique ?
3. Vous a-t-on remis une copie de votre plan de traitement ?

Établissement des objectifs/personnalisation :

1. Vous a-t-on demandé de parler de vos objectifs en ce qui concerne la manière de prendre soin de votre condition chronique ?
2. Vous a-t-on aidé à fixer des objectifs spécifiques pour améliorer votre alimentation ou votre activité physique ?
3. Vous a-t-on montré comment ce que vous avez fait pour prendre soins de vous-même a influencé votre condition chronique ?
4. Vous a-t-on remis une liste écrite des choses que vous devriez faire pour améliorer votre santé ?
5. Étiez-vous satisfait de la manière dont vos soins étaient organisés ?

Coordination des soins :

1. Vous a-t-on dirigé vers un diététiste, un éducateur en matière de santé ou un conseiller ?
2. Vous a-t-on dit comment vos visites chez d'autres genres de médecins (p. ex., spécialiste, chirurgien) contribuaient à votre traitement ?
3. Vous a-t-on demandé comment se passaient vos visites chez les autres médecins ?
4. A-t-on communiqué avec vous après une visite pour savoir comment les choses se passaient ?

Globalité des soins :

Depuis que vous utilisez CONCERTO+, avez-vous...

1. Pu obtenir un rendez-vous avec un professionnel de la clinique ?
2. Été aidé(e) lorsque vous en aviez besoin ?
3. Obtenue un rendez-vous de suivi de votre condition de santé ?
4. Eu besoin d'entrer en contact avec un professionnel de l'équipe ou reçu une réponse de l'un d'entre eux à la suite de votre appel téléphonique ?
5. L'impression que votre infirmière coordonne l'ensemble de vos soins ?

¹ Adapté de : McIntosh, CN. Examen de la validité factorielle de certains modules de l'Enquête canadienne sur l'expérience des soins de santé primaires. Statistique Canada, Division de l'information et de la recherche sur la santé. Juillet 2008.

² Ces critères ont été développés initialement et validés par Glasgow et collaborateurs : Glasgow RE, Wagner EW, Schaefer J, MahoneyLD, Reid RJ, Greene SM. 2005. Development and validation of the patient assessment of chronic illness care (PACIC). Medical Care. 43, 5: 436-444.

6. Le sentiment que l'équipe du Programme a tenu compte de votre problème de santé ?
7. Pu constater que l'on a tenu compte de vos consultations avec d'autres professionnels de la santé que ceux de l'équipe du Programme ?
8. Pu vous faire aider à comprendre vos résultats de tests (par exemple : test de laboratoire, prise de pression, etc.) ?
9. Obtenue une réponse lors d'une situation urgente pour vous ?

3. Acceptation de CONCERTO+

Outils utilisé

Questionnaire basé sur le Modèle d'acceptation de la technologie

Critères

Facilité d'utilisation perçue :

1. Mon interaction avec le système CONCERTO+ est claire et compréhensible
2. Je trouve qu'il est facile de demander au système CONCERTO+ de faire ce que je veux
3. L'utilisation de CONCERTO+ améliorera mon suivi
4. L'utilisation de CONCERTO+ améliorera mon efficacité à me prendre en charge

Utilité perçue :

1. L'utilisation de CONCERTO+ améliorera mon état de santé
2. Je trouve que CONCERTO+ est un outil utile pour le suivi de mon état de santé
3. L'utilisation de CONCERTO+ plus intéressant.
4. J'aime travailler avec l'ordinateur.
5. Je cherche des aspects de mon métier qui demande d'utiliser l'ordinateur

Intention comportementale d'utiliser :

1. Je vais utiliser CONCERTO+ dans le futur.
2. J'établis un plan pour utiliser CONCERTO+

4. Utilisation de CONCERTO+

Outil utilisé

Registres d'utilisation de CONCERTO+

Critères

Registres (*Logs*)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

Supplementary File 2: Outcome measures and items (original English version)

1. Patient Activation	
Tool used	
<i>Patient Activation Measure-PAM-13</i>	
Criteria¹	
1. When all is said and done, I am the person who is responsible for managing my health condition. 2. Taking an active role in my own healthcare is the most important factor in determining my health and ability to function. 3. I am confident that I can take actions that will help prevent or minimize some symptoms or problems associated with my health condition. 4. I know what each of my prescribed medications does. 5. I am confident I can tell when I need to go get medical care and when I can handle a health problem. 6. I am confident I can tell my health provider the concerns I have even when he or she does not ask. 7. I am confident I can follow through on the medical treatment I need to do at home. 8. I understand the nature and causes of my health condition. 9. I know the different medical treatment options available for my health condition. 10. I have been able to maintain the lifestyle changes I have made for my health. 11. I know how to prevent further problems with my health condition. 12. I am confident I can find a solution when new situations or problems arise with my health condition. 13. I am confident I can maintain lifestyles changes, like diet and exercise, even during times of stress.	
Results measurement	
Scoring (for each criteria): <ul style="list-style-type: none"> ▪ Strongly disagree = 1 ▪ Disagree = 2 ▪ Agree = 3 ▪ Strongly agree = 4 	
Activation level (converted into a score of 100): <ol style="list-style-type: none"> 1. Not believing that activation is important (≤ 47) 2. Lack of knowledge or confidence to take action (47.1-55.1) 3. Beginning to take action (55.2-67) 4. Taking action (≥ 67.1) 	

53
54
55
56
57
58
59
60

¹ Adapted from: Moljord I E O, Lara-Cabrera ML, Perestelo-Pérez L, Rivero-Santana A, Eriksen L, Linaker OM. Psychometric properties of Patient Activation Measure-13 among out-patients waiting for mental health treatment: a validation study in Norway. *Patient education and counseling*. 2015;98(11):1410-1417.

2. Impacts of the use of CONCERTO+

Tool used

Survey used for the assessment of the CHP pilot

Criteria¹

Problem-solving/Advice

1. Have you been asked how your illness affects your life?
2. Have you been helped in planning ahead to take care of your illness even in hard times?
3. Did your care providers ask about your values and traditions when they recommended treatment?
4. Have you been helped in drawing up a treatment plan that you could follow in your daily life?

Delivery system design/Decision support

1. Have you been asked about your health habits?
2. Have you been encouraged to go to a specific group or class to help you cope with your chronic illness?
3. Have you been given a copy of your treatment plan?

Goal-setting/Tailoring

1. Have you been asked to talk about your goals in the context of receiving care for your chronic condition?
2. Have you been helped in setting specific goals to improve your diet or fitness?
3. Have you been given a written list of things you should do to improve your health?
4. Have you been shown how taking proper care of your illness influenced your condition?
5. Are you satisfied that your care was well organized?

Follow-up/Coordination

1. Have you been referred to a dietitian, health educator, or counselor?
2. Have you been told how your visits with other doctors were going?
3. Have you been told how your visits with other types of doctors, such as a specialist or a surgeon, helped in your treatment?
4. Have you been asked how your visits with other doctors were going?
5. Have you been contacted after a visit to see how things were going?

Overall care²

Since you began using CONCERTO+

1. Have you had an appointment with a professional from the clinic?
2. Have you received help when you were in need?
3. Have you had a follow-up appointment for your health condition?
4. Have you been helped through contact with a professional from the team or by receiving an answer from one of the team members after a phone call?
5. Have you had the feeling that your nurse coordinates all of your care?
6. Have you had the feeling that your health problems are being taken into account by the Program team?
7. Have you noticed that your visits with other health professionals are being taken into account by the Program team?
8. Have you been helped in understanding your test results (e.g. laboratory test, pressure tap, etc.)?
9. Have you received an answer in emergency situations?

¹ These criteria were originally developed and validated by Glasgow RE, Wagner EW, Schaefer J, Mahoney LD, Reid RJ, Greene SM. 2005. Development and validation of the patient assessment of chronic illness care (PACIC). *Medical Care*. 43, 5: 436–444.

² Adapted from McIntosh, CN. Examen de la validité factorielle de certains modules de l'Enquête canadienne sur l'expérience des soins de santé primaires. *Statistique Canada, Division de l'information et de la recherche sur la santé*. July 2008.

3. Acceptance of CONCERTO+

Tool used

Survey based on the *Technology Acceptance Model*

Criteria

Perceived ease of use

1. My interaction with CONCERTO+ is clearer and more comprehensive.
2. I find it is easy to get CONCERTO+ to do what I want it to do.
3. The use of CONCERTO+ will improve my follow-up.
4. The use of CONCERTO+ will improve the effectiveness of my care.

Perceived usefulness

1. The use of CONCERTO+ will improve my health condition.
2. I find CONCERTO+ to be a useful tool for the follow-up of my health condition.
3. The use of CONCERTO+ is interesting.
4. I like to use a smart phone or a tablet to look for health information.
5. I'm eager to use technology to manage my health condition.

Behavioural intention to use

1. I'm going to use CONCERTO+ in the future.
2. Using CONCERTO+ is part of my plan.

4. The use of CONCERTO+

Tool used

CONCERTO+ logs use

Criteria

Logs

Supplementary File 3: ExpandNet recommendations for scaling up (WHO, 2013) Original English version

1. Engage in a participatory process involving key stakeholders.
2. Ensure the relevance of the proposed innovation.
3. Reach a consensus on expectations for scale up.
4. Tailor the innovation to the socio-cultural and institutional settings.
5. Keep the innovation as simple as possible.
6. Test the innovation in the variety of socio-cultural and institutional settings where it will be scaled up.
7. Test the innovation under routine operating conditions and existing resource constraints of the health system.
8. Develop plans to assess and document the process of implementation.
9. Advocate with donors and other sources of funding for financial support beyond the pilot stage.
10. Prepare to advocate for necessary changes in policies, regulations, and other health systems components.
11. Develop plans for how to promote learning and disseminate information.
12. Plan on being cautious about initiating scale up before the required evidence is available.

Supplementary File 4:Recommandations d'ExpandNet pour le passage à l'échelle (OMS, 2013) (French translation)

1. Engager un processus participatif impliquant les principales parties prenantes
2. Assurer la pertinence de l'innovation proposée
3. Trouver un consensus sur les attentes à propos du passage à grande échelle
4. Ajuster l'innovation aux cadres socioculturels et institutionnels
5. Garder l'innovation aussi simple que possible
6. Tester l'innovation dans la variété de cadres socioculturels et institutionnels où elle passera à grande échelle
7. Tester l'innovation dans les conditions de fonctionnement de routine et sous les contraintes de ressource actuelles du système de santé
8. Planifier l'évaluation et la documentation du processus de mise en œuvre
9. Plaider auprès des bailleurs de fonds et autres sources de financement pour un soutien financier au-delà de la phase pilote
10. Se préparer à plaider pour des changements nécessaires dans les politiques, règlements et autres composantes des systèmes de santé
11. Planifier la façon de promouvoir l'apprentissage et la diffusion de l'information
12. Se préparer à la prudence quant au lancement du passage à grande échelle avant l'obtention des preuves requises

Supplementary File 5: Ethical and funding approval (English translation)**ETHICS APPROVAL**

Research project involving human beings or the consultation of personal information

This research project is reviewed in accordance with the ethical procedures management of research with human beings of Université Laval **by the sectorial committee of research ethics in health science**

Project title	Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare
Researcher's name	Marie-Pierre Gagnon
Approval number	2018-067 / 01-06-2018
Decision date	June 1, 2018
Approval expiration date	July 1, 2019

After reviewing the information and documents it has been provided, the committee notes that the project respects ethical principles of research with human beings. It takes note of the written confirmation of the researcher that she is aware of the follow-up actions¹ associated with ethical approval of this project and that she has agreed to apply them. Therefore, the committee approves this project for one year.

June 6, 2018

Mahmoud Rouabhia, Chair of the
Research Ethics Committee in
Health Sciences

¹ Follow-up action reminder on the next page.

Follow-up actions associated with ethics approval

For the project entitled **Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare** (file number: 2018-067)




1. Notify the Committee in writing without undue delay (independent of its statutory meeting agenda) in the following situations:
 - Any changes to the project, as approved this day, that would include changes to the choice of participants, to recruitment, to the obtention of consent, to the collection of data, and/or to the incurred risks or disadvantages before the application of any such changes (the template of the letter requesting an amendment is available on the CÉRUL website).
 - Any changes to the instrument used for recruitment (ads, posters, or other instruments), to the confirmation of consent (consent form, information sheet, or other forms of confirmation), or to the collection of data (survey, interview grid, or other data collection mechanisms) by providing the latest version of the document under consideration, where changes will be highlighted, before its use.
 - Any unexpected and serious event (e.g. psychological distress of a participant, threat against a person, unexpected or side effects of a product, a drug or a test) that may occur in the course of the current project and would involve a participant, by completing the VRR-EI form available on the CÉRUL website.
 - Any early termination of this research for any reason, be it funded or not, including reasons due to suspension or cancellation on the part of the granting agency.
2. Until the project is finished, and not only for recruitment, submit an annual renewal request for approval by providing a report on research progress, the number of recruited participants, and the difficulties encountered along the way, by using the VRR-107 form. The renewal request must be sent to the committee at least 30 days before the end date of the approval, independent of the statutory meeting agenda.

I, the undersigned, Marie-Pierre Gagnon, declare that I **have read and understood the above follow-up actions associated with ethics approval** and agree to apply them during the entire research project for which I am the principal researcher.

Signature of the principal researcher: _____

Date: 2018-06-04

Supplementary File 6: Ethical approval (original French version)

	
Vice-rectorat à la recherche et à la création Comité d'éthique de la recherche	
<h2>APPROBATION DE L'ÉTHIQUE</h2>	
Projet de recherche impliquant des êtres humains ou la consultation de renseignements personnels	
Ce projet de recherche a été examiné en conformité avec les <i>Modalités de gestion de l'éthique de la recherche sur des êtres humains</i> de l'Université Laval, par le Comité sectoriel d'éthique de la recherche en sciences de la santé	
Projet intitulé :	Personnaliser CONCERTO : L'expérience patient optimisée pour des soins intégrés, coordonnés et efficaces
Nom du chercheur :	Madame Marie-Pierre Gagnon
Numéro d'approbation :	2018-067 / 01-06-2018
Date de décision :	1 ^{er} juin 2018
Date d'expiration de l'approbation :	1 ^{er} juillet 2019
<p>Après examen des informations et des documents qui lui ont été transmis, le Comité a constaté que ce projet respecte les principes d'éthique de la recherche avec des êtres humains. Il prend acte de la confirmation écrite de la chercheuse à l'effet qu'elle a pris connaissance des mesures de suivi¹ associées à l'émission de l'approbation éthique de son projet et qu'elle accepte de les appliquer. Par conséquent, le Comité approuve ce projet pour un an.</p>	
	
<hr/> Mahmoud Rouabhia , président Comité d'éthique de la recherche en sciences de la santé	Date
<hr/> ¹ Rappel des mesures de suivi au verso	
Maison Michael-John-Brophy 2241, chemin Sainte-Foy Québec (Québec) G1V 0A6 CANADA	418 656-2131, poste 4506 Télécopieur : 418 656-2840 cer@vrr.ulaval.ca www.cer.ulaval.ca



Vice-rectorat à la recherche et à la création
Comité d'éthique de la recherche

Mesures de suivi associées à l'approbation éthique

Pour le projet intitulé : **Personnaliser CONCERTO : L'expérience patient optimisée pour des soins intégrés, coordonnés et efficients** (numéro de dossier : 2018-067)

1. Informer le Comité par écrit et dans les meilleurs délais (indépendamment du calendrier de ses réunions statutaires) des situations suivantes si elles se présentent :
 - de **toute modification au projet**, comme il a été approuvé en ce jour, qui comporterait des changements dans le choix des participants, dans le recrutement, dans la manière d'obtenir leur consentement, de réaliser la collecte des données ou encore, dans les risques ou inconvénients encourus par la participation, et ce, préalablement à l'application de ce changement (modèle de lettre de demande d'amendement disponible sur le site Internet des CÉRUL) ;
 - de **toute modification** qui serait apportée à un **instrument utilisé pour le recrutement** (annonces, affiches, etc.), pour confirmer le **consentement** (formulaire de consentement, feuillet d'information, etc.) ou pour effectuer la **collecte** des données (questionnaire, grille d'entrevue, etc.) en fournissant la nouvelle version du document concerné, où les modifications auront été mises en évidence, préalablement à son utilisation ;
 - de **tout événement imprévu et sérieux** (ex. : détresse psychologique d'un participant, menace proférée à l'égard d'une personne, effets secondaires ou imprévus ou indésirables d'un produit, d'un médicament ou d'un test, etc.) qui surviendrait dans le déroulement d'une activité du présent projet et qui impliquerait un participant, en complétant le formulaire VRR-EI disponible sur le site Internet des CÉRUL ;
 - de **l'interruption prématurée de ce projet de recherche** pour une raison quelconque qu'il soit financé ou non, y compris en raison de la suspension ou de l'annulation de l'approbation d'un organisme subventionnaire.
2. Tant que le projet ne sera pas terminé, et non seulement le recrutement, présenter annuellement une **demande de renouvellement** de l'approbation, en fournissant un rapport sur le déroulement de la recherche, le nombre de participants recrutés et, le cas échéant, sur les difficultés rencontrées en cours de réalisation, à l'aide du formulaire VRR-107. La demande de renouvellement doit être transmise au Comité dans un délai de 30 jours avant la date de fin de l'approbation, indépendamment du calendrier des réunions statutaires.

Maison Michael-John-Brophy
2241, chemin Sainte-Foy
Québec (Québec) G1V 0A6
CANADA

418 656-2131, poste 4506
Télécopieur : 418 656-2840
cer@vrr.ulaval.ca
www.cerul.ulaval.ca

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

2 3 4 5 **Supplementary File 7: Consent form for validation cycles**

6 This research entitled "Optimizing patient usability experience with an eHealth platform for embedded, coordinated
7 and efficient healthcare" is conducted by Marie-Pierre Gagnon, from faculty of nursing at Université Laval.

8
9 Before you agree to take part in this research project, please take the time to read and understand the following
10 information. This document will explain you the aim of this research project, his process, advantages, risks and
11 disadvantages. We invite you to ask all questions you may deem necessary to the research staff. You can find
12 their contact details at the end of the form.
13
14

15 **Type of study**

16 This research project aims to develop, implement and evaluate a user-centered, multifunctional and personalized
17 eHealth platform (CONCERTO+) to promote a more active patient role in chronic disease management and
18 decision-making, satisfaction towards healthcare services and quality of life. Specific objectives are to:

- 19 1) develop a module of a multifunctional and personalized eHealth platform integrated to the CHP (Concerto Health
20 Program) for patients and caregivers allowing them to engage in the follow-up and management of their chronic
21 diseases;
- 22 2) test the integration of CONCERTO+ in monitoring care pathways of three frequent co-existing chronic diseases
23 (diabetes, hypertension, dyslipidemia) and assess the usefulness and acceptability of the solution for patients with
24 chronic diseases and their caregivers;
- 25 3) assess the scalability of the CONCERTO+ solution.
26
27
28
29

30 **The course of the participation:**

31 Validation of the prototype of the application CONCERTO+

32 Your participation in this research will consist in validating the prototype of the application CONCERTO+. In
33 practical terms, you should go to the usability laboratory of Université Laval lead by Dr Holly Witteman. The
34 validation of the application will be done either on a smartphone or a digital tablet. The aim is to collect your input
35 in visual presentation, content, usability of the application, the pros and cons and any consideration of the
36 application developed. Iterative testing via three validation sessions will be organized. If you agree to participate
37 to the validation cycles, your participation may have incur parking and travel expenses. In addition, the participation
38 in each validation cycle requires approximately one and a half hour of your time.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

Potential benefits and risks or disadvantages related to your participation

There are no direct benefits for the participants. However, this research enables improve the adaptation and value of the CHP in order to provide a multifunctional and personalized eHealth platform, to promote a more active patient and informal care givers role in chronic disease management.

Compensation

If you participate in validation cycles, we can provide you a lump sum amount of 18 \$ for the time you have allocated for this activity. This sum will be returned in each validation session.

Voluntary participation and right to withdraw

You are free to participate to this research project. You may voluntarily withdraw at any time without any justification and with no adverse consequences or without prejudice. However If you decide so, It is important to inform the research team whose contact details are included at the end of the document. All your personal information will be destroyed.

Confidentiality and data management

The following measures will be applied to ensure your private information stays private:

- Your name will not be mentioned in any report;
- The various documents will be codified and only the investigator and his team will have access to the list of names and codes;
- Your individual results will never be shared;
- In the interest of scientific rigor, the electronic data will be kept in a folder with a password on the web server of the Canada Research Chair on Technology and Practices in Health at Université Laval. They will be destroyed only five years after the end of the research, in December 2024;
- This research will be published in scientific reviews and no one can able to identify you;
- A short summary of the research results will be sent to you if requested by indicating the address where you would like to receive the document, just after the blank space provided for your signature.

Acknowledgment

Your collaboration is useful to achieve this study, thank you for your participation.

Additional information

If you have any question on the research, the involvement of your participation or if you want to withdraw from this research, please contact: Mame Awa Ndiaye, research coordinator, Amélie Lampron, research coordinator or Marie-Pierre Gagnon, principal investigator at the following coordinates:

- Mame Awa Ndiaye: mame-awa.ndiaye.ciusssc@ssss.gouv.qc.ca
- Amélie Lampron: amelie.lampron2.ciusssc@ssss.gouv.qc.ca
- Marie-Pierre Gagnon: marie-pierre.gagnon@fsi.ulaval.ca

Complaints and criticism

Any complaint and criticism related to this research project will be addressed to the Ombudsman office at Université Laval:

Pavillon Alphonse-Desjardins, bureau 3320
2325, rue de l'Université
Université Laval
Québec (Québec) G1V 0A6
Information - Secretariat : (418) 656-3081

Project approved by the sectorial committee of research ethics in health science of Université Laval (Approval number 2018-067), June 1st 2018. MPG

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

2
3
4 Toll-free line: 1-866-323-2271

5 Email: info@ombudsman.ulaval.ca

6 Signatures

7
8 I, the undersigned _____ freely consent to participate to the research entitled:
9
10 «Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient
11 healthcare». I have read and understood the aim, type, advantages, risks and disadvantages of the research
12 project. I'm satisfied with the explanations, further details and responses received from the investigator, where
13 appropriate, about my participation to this project.
14
15

16
17
18 _____
19 Participant signature

_____ Date

20
21 A short summary of the search results will be sent to you if requested by indicating the address where you would
22 like to receive the document. **The results will not be available before December 20th. If your address changes
23 by that date, you are invited to inform the research team, the new address you wish to receive the
24 document.**
25

26 I wish receive a short summary

No, I would prefer not to receive summary

27
28
29 I would like to receive the summary at the following email address or mailing address:

30
31 _____
32
33 _____
34
35

36 I explained the aim, type of the study, advantages, risks and disadvantages of the research project I have
37 answered to the best of my knowledge the questions asked and have verified the understanding of the
38 participant.
39

40
41 _____
42 Investigator or research coordinator signature

_____ Date

43
44 Copy of the participant.
45
46
47
48
49
50
51
52
53
54
55
56
57

58 Project approved by the sectorial committee of research ethics in health science of Université Laval (Approval number 2018-067),
59 June 1st 2018. MPG

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare
2
3

4 **List of the team members/ Names of project**
5 **partners**

Role in the project

6 Marie-Pierre Gagnon

Specialist of patient engagement and eHealth
7 technology assessment

8 Christian Chabot

Patient partner, co-designer of the project

9 Guylaine Chabot, Alain Larouche

Technological partners

10 France Légaré, Anik Giguère, Annie LeBlanc

Experts in shared decision making

11 Samira Rahimi Abbasgholizadeh

Expert in decision aids tools

12 Jean-Paul Fortin, Aude Motulsky, Claude Sicotte

Experts in evaluation of health information
13 systems

14 Holly Witteman

Expert in adaptation of user-centered technologies

15 Ronald Buyl

Expert in medical informatics and biostatistics

16 Carole Délétroz

Expert in health literacy

17 Erik Kavanagh, Frédéric Lépinay, Jacynthe
18 Roberge

Specialists in application development and design

19 Amélie Lampron, Mame Awa Ndiaye

Research coordinators

Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

Supplementary File 8: Consent form (patients and informal caregivers) 2a

This research entitled "Optimizing patient usability experience with an eHealth platform for embedded, coordinated and efficient healthcare" is conducted by Marie-Pierre Gagnon, from faculty of nursing at Université Laval.

Before you agree to take part in this research project, please take the time to read and understand the following information. This document will explain you the aim of this research project, his process, advantages, risks and disadvantages. We invite you to ask all questions you may deem necessary to the research staff. You can find their contact details at the end of the form.

Type of study

This research project aims to develop, implement and evaluate a user-centered, multifunctional and personalized eHealth platform (CONCERTO+) to promote a more active patient role in chronic disease management and decision-making, satisfaction towards healthcare services and quality of life. Specific objectives are to:

- 1) develop a module of a multifunctional and personalized eHealth platform integrated to the CHP (Concerto Health Program) for patients and caregivers allowing them to engage in the follow-up and management of their chronic diseases;
- 2) test the integration of CONCERTO+ in monitoring care pathways of three frequent co-existing chronic diseases (diabetes, hypertension, dyslipidemia) and assess the usefulness and acceptability of the solution for patients with chronic diseases and their caregivers;
- 3) assess the scalability of the CONCERTO+ solution.

The course of the participation:

1) Validation of the prototype of the application CONCERTO+

Your participation in this research will consist in using the application CONCERTO+ (intervention group) or to continue your usual health follow-up (control group). For the participants of the intervention group, the use of the application will be explained to you by the members of the research team. You will complete a short questionnaire at the beginning and at the end of a six months period use, which will focus on the following points:

- Health management
- Feelings in competency and self confidence in health management
- Impacts of CONCERTO+ use
- The use of CONCERTO+

2) Focus group

Your participation in this research consists in participating in a focus group composed of 8 -12 people. The discussion will last approximately two hours and will focus on conditions and factors related to the wide-scale dissemination of the solution CONCERTO+.

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

2 3 4 5 **Potential benefits and risks or disadvantages related to your participation**

6 There are no direct benefits for the participants. However, participating in this research enables improve the
7 adaptation and value of the CHP in order to provide a multifunctional and personalized eHealth platform, to
8 promote a more active patient and informal care givers role in chronic disease management.

9 10 **Compensation**

11 If you accept to participate, a lump sum of 50 \$ will be offered to you for the time you have allocated for this
12 activity. This sum will be returned to you during the focus group discussion.

13 14 15 **Voluntary participation and right to withdraw**

16 You are free to participate to this research project. You may voluntarily withdraw at any time without any
17 justification and with no adverse consequences or without prejudice. However If you decide so, It is important to
18 inform the research team whose contact details are included at the end of the document. All your personal
19 information will be destroyed.

20 21 22 **Confidentiality and data management**

23 The following measures will be applied to ensure your private information stays private:

- 24 •Your name will not be mentioned in any report;
- 25 •The various documents will be codified and only the investigator and his team will have access to the list of
26 names and codes;
- 27 • Your individual results will never be shared;
- 28 • In the interest of scientific rigor, the electronic data will be kept in a folder with a password on the web server of
29 the Canada Research Chair on Technology and Practices in Health at Université Laval. They will be destroyed
30 only five years after the end of the research, in December 2024;
- 31 • This research will be publicated in scientific reviews and no one can able to identify you;
- 32 • A short summary of the research results will be sent to you if requested by indicating the address where you
33 would like to receive the document, just after the blank space provided for your signature.

34 35 36 **Acknowledgment**

37 Your collaboration is useful to achieve this study, thank you for your participation.

38 39 40 **Additional information**

41 If you have any question on the research, the involvement of your participation or if you want to withdraw from this
42 research, please contact: Mame Awa Ndiaye, research coordinator, Amélie Lampron, research coordinator or
43 Marie-Pierre Gagnon, principal investigator at the following coordinates:

- 44 • Mame Awa Ndiaye: mame-awa.ndiaye.ciusscn@ssss.gouv.qc.ca
- 45 • Amélie Lampron: amelie.lampron2.ciusscn@ssss.gouv.qc.ca
- 46 • Marie-Pierre Gagnon: marie-pierre.gagnon@fsi.ulaval.ca

47 48 49 **Complaints and criticism**

50 Any complaint and criticism related to this research project will be addressed to the Ombudsman office at
51 Université Laval:

52 Pavillon Alphonse-Desjardins, bureau 3320
53 2325, rue de l'Université
54 Université Laval
55 Québec (Québec) G1V 0A6
56 Information - Secretariat : (418) 656-3081

57
58 Project approved by the sectorial committee of research ethics in health science of Université Laval (**Approval number 2018-067**),
59 June 1st 2018. MPG

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare
 2
 3

4 Toll-free line: 1-866-323-2271

5 Email: info@ombudsman.ulaval.ca
 6
 7

8 Signatures

9 I, the undersigned _____ freely consent to participate to the research entitled:
 10 «Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient
 11 healthcare». I have read and understood the aim, type, advantages, risks and disadvantages of the research
 12 project. I' m satisfied with the explanations, further details and responses received from the investigator, where
 13 appropriate, about my participation to this project.
 14

15
 16 _____
 17 Participant signature

_____ Date

18
 19 Do you wish to participate in the first step of this research involving the use of application CONCERTO+ and
 20 the completion of two questionnaires on the active involvement?
 21

22 Yes, i accept to participate

No, i would prefer not to participate

23
 24 Do you wish to participate in the second step of the project involving the participation in a focus group on
 25 factors and conditions related to the wide-scale dissemination of the solution CONCERTO+?
 26

27
 28 Yes, i accept to participate

No, i would prefer not to participate

29
 30 A short summary of the search results will be sent to you if requested by indicating the address where you would
 31 like to receive the document. **The results will not be available before December 20th. If your address changes
 32 by that date, you are invited to inform the research team, the new address you wish to receive the
 33 document.**
 34

35 I wish receive a short summary

No, I would prefer not to receive summary

36 I would like to receive the summary at the following email address or mailing address:
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49

50 _____
 51 Investigator or research coordinator signature

_____ Date

52 **Copy of the participant.**
 53
 54
 55
 56
 57

58 Project approved by the sectorial committee of research ethics in health science of Université Laval (**Approval number 2018-067**),
 59 June 1st 2018. MPG

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare
2
3

4 **Supplementary File 9: Consent form (interviews)**

5
6 This research entitled "Optimizing patient usability experience with an eHealth platform for embedded, coordinated
7 and efficient healthcare" is conducted by Marie-Pierre Gagnon, from faculty of nursing at Université Laval.
8
9

10 Before you agree to take part in this research project, please take the time to read and understand the following
11 information. This document will explain you the aim of this research project, his process, advantages, risks and
12 disadvantages. We invite you to ask all questions you may deem necessary to the research staff. You can find
13 their contact details at the end of the form.
14
15

16 **Type of study**

17 This research project aims to develop, implement and evaluate a user-centered, multifunctional and personalized
18 eHealth platform (CONCERTO+) to promote a more active patient role in chronic disease management and
19 decision-making, satisfaction towards healthcare services and quality of life. Specific objectives are to:
20

21 1) develop a module of a multifunctional and personalized eHealth platform integrated to the CHP (Concerto Health
22 Program) for patients and caregivers allowing them to engage in the follow-up and management of their chronic
23 diseases;
24

25 2) test the integration of CONCERTO+ in monitoring care pathways of three frequent co-existing chronic diseases
26 (diabetes, hypertension, dyslipidemia) and assess the usefulness and acceptability of the solution for patients with
27 chronic diseases and their caregivers;
28

29 3) assess the scalability of the CONCERTO+ solution.
30

31 **The course of the participation:**

32 Your participation to this research consists in participating in one-on-one semi-structured interview with a
33 member of the team. This interview will last approximately 30 minutes and will focus on the following points:
34

- 35 • Factors facilitating the use of CONCERTO+
- 36 • Factors limiting the use of CONCERTO+
- 37 • Support to the use of CONCERTO+ by health professionals
- 38 • Expansion of CONCERTO+
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57

1 Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

2 3 4 5 **Potential benefits and risks or disadvantages related to your participation**

6 There are no direct benefits for the participants. However, participating in this research enables improve the
7 adaptation and value of the CHP in order to provide a multifunctional and personalized eHealth platform, to
8 promote a more active patient and informal care givers role in chronic disease management.

9 10 **Compensation**

11 If you accept to participate, a lump sum of 50 \$ will be offered to you for the time you have allocated for this
12 activity. This sum will be returned to you during the focus group discussion.

13 14 15 **Voluntary participation and right to withdraw**

16 You are free to participate to this research project. You may voluntarily withdraw at any time without any
17 justification and with no adverse consequences or without prejudice. However If you decide so, It is important to
18 inform the research team whose contact details are included at the end of the document. All your personal
19 information will be destroyed.

20 21 22 **Confidentiality and data management**

23 The following measures will be applied to ensure your private information stays private:

- 24 •Your name will not be mentioned in any report;
- 25 •The various documents will be codified and only the investigator and his team will have access to the list of
26 names and codes;
- 27 • Your individual results will never be shared;
- 28 • In the interest of scientific rigor, the electronic data will be kept in a folder with a password on the web server of
29 the Canada Research Chair on Technology and Practices in Health at Université Laval. They will be destroyed
30 only five years after the end of the research, in December 2024;
- 31 • This research will be publicated in scientific reviews and no one can able to identify you;
- 32 • A short summary of the research results will be sent to you if requested by indicating the address where you
33 would like to receive the document, just after the blank space provided for your signature.

34 35 36 **Acknowledgment**

37 Your collaboration is useful to achieve this study, thank you for your participation.

38 39 40 **Additional information**

41 If you have any question on the research, the involvement of your participation or if you want to withdraw from this
42 research, please contact: Mame Awa Ndiaye, research coordinator, Amélie Lampron, research coordinator or
43 Marie-Pierre Gagnon, principal investigator at the following coordinates:

- 44 • Mame Awa Ndiaye: mame-awa.ndiaye.ciussscn@ssss.gouv.qc.ca
- 45 • Amélie Lampron: amelie.lampron2.ciussscn@ssss.gouv.qc.ca
- 46 • Marie-Pierre Gagnon: marie-pierre.gagnon@fsi.ulaval.ca

47 48 49 **Complaints and criticism**

50 Any complaint and criticism related to this research project will be addressed to the Ombudsman office at
51 Université Laval:

52 Pavillon Alphonse-Desjardins, bureau 3320
53 2325, rue de l'Université
54 Université Laval
55 Québec (Québec) G1V 0A6
56 Information - Secretariat : (418) 656-3081

57
58 Project approved by the sectorial committee of research ethics in health science of Université Laval (**Approval number 2018-067**),
59 June 1st 2018. MPG

Research title: Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare

Toll-free line: 1-866-323-2271

Email: info@ombudsman.ulaval.ca

Signatures

I, the undersigned _____ freely consent to participate to the research entitled: «Personalize concerto: Patient usability experience optimized for embedded, coordinated, and efficient healthcare». I have read and understood the aim, type, advantages, risks and disadvantages of the research project. I'm satisfied with the explanations, further details and responses received from the investigator, where appropriate, about my participation to this project.

Participant signature

Date

A short summary of the search results will be sent to you if requested by indicating the address where you would like to receive the document. **The results will not be available before December 20th. If your address changes by that date, you are invited to inform the research team, the new address you wish to receive the document.**

I wish receive a short summary No, I would prefer not to receive summary

I would like to receive the summary at the following email address or mailing address:

I explained the aim, type of the study, advantages, risks and disadvantages of the research project I have answered to the best of my knowledge the questions asked and have verified the understanding of the participant.

Investigator or research coordinator signature

Date

Copy of the participant.



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

Pages
6
9

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

13
13
13
13-15

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	15
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	17
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	17
Methods: Assignment of interventions (for controlled trials)			
Allocation:			19
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	19
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	
Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	20
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	21
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	

1			
2		26b	Additional consent provisions for collection and use of
3			participant data and biological specimens in ancillary studies, if
4			applicable
5			
6	Confidentiality	27	How personal information about potential and enrolled
7			participants will be collected, shared, and maintained in order
8			to protect confidentiality before, during, and after the trial
9			
10			
11	Declaration of	28	Financial and other competing interests for principal
12	interests		investigators for the overall trial and each study site
13			
14	Access to data	29	Statement of who will have access to the final trial dataset, and
15			disclosure of contractual agreements that limit such access for
16			investigators
17			
18	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for
19	post-trial care		compensation to those who suffer harm from trial participation
20			
21	Dissemination	31a	Plans for investigators and sponsor to communicate trial
22	policy		results to participants, healthcare professionals, the public, and
23			other relevant groups (eg, via publication, reporting in results
24			databases, or other data sharing arrangements), including any
25			publication restrictions
26			
27			
28		31b	Authorship eligibility guidelines and any intended use of
29			professional writers
30			
31		31c	Plans, if any, for granting public access to the full protocol,
32			participant-level dataset, and statistical code
33			
34			
35	Appendices		
36			
37	Informed consent	32	Model consent form and other related documentation given to
38	materials		participants and authorised surrogates
39			
40	Biological	33	Plans for collection, laboratory evaluation, and storage of
41	specimens		biological specimens for genetic or molecular analysis in the
42			current trial and for future use in ancillary studies, if applicable
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.